<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Chlorpromazine versus penfluridol for schizophrenia - Nikvarz, N - 2017 | Cochrane Library</title> <meta content="Chlorpromazine versus penfluridol for schizophrenia - Nikvarz, N - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011831.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Chlorpromazine versus penfluridol for schizophrenia - Nikvarz, N - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011831.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011831.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Chlorpromazine versus penfluridol for schizophrenia" name="citation_title"/> <meta content="Naemeh Nikvarz" name="citation_author"/> <meta content="Kerman University of Medical Sciences" name="citation_author_institution"/> <meta content="Mostafa Vahedian" name="citation_author"/> <meta content="Kerman University of Medical Sciences" name="citation_author_institution"/> <meta content="Navid Khalili" name="citation_author"/> <meta content="Kerman University of Medical Sciences" name="citation_author_institution"/> <meta content="navidkhalili2000@yahoo.com" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD011831.pub2" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/09/23" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011831.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011831.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011831.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Akathisia, Drug‐Induced [epidemiology]; Antipsychotic Agents [adverse effects, *therapeutic use]; Chlorpromazine [adverse effects, *therapeutic use]; Length of Stay; Penfluridol [adverse effects, *therapeutic use]; Randomized Controlled Trials as Topic; Schizophrenia [*drug therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011831.pub2&amp;doi=10.1002/14651858.CD011831.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011831.pub2&amp;doi=10.1002/14651858.CD011831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011831.pub2&amp;doi=10.1002/14651858.CD011831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011831.pub2&amp;doi=10.1002/14651858.CD011831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011831.pub2&amp;doi=10.1002/14651858.CD011831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011831.pub2&amp;doi=10.1002/14651858.CD011831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011831.pub2&amp;doi=10.1002/14651858.CD011831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011831.pub2&amp;doi=10.1002/14651858.CD011831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011831.pub2&amp;doi=10.1002/14651858.CD011831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011831.pub2&amp;doi=10.1002/14651858.CD011831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011831.pub2&amp;doi=10.1002/14651858.CD011831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011831.pub2&amp;doi=10.1002/14651858.CD011831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011831.pub2&amp;doi=10.1002/14651858.CD011831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011831.pub2&amp;doi=10.1002/14651858.CD011831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011831.pub2&amp;doi=10.1002/14651858.CD011831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011831.pub2&amp;doi=10.1002/14651858.CD011831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011831.pub2&amp;doi=10.1002/14651858.CD011831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011831.pub2&amp;doi=10.1002/14651858.CD011831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011831.pub2&amp;doi=10.1002/14651858.CD011831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011831.pub2&amp;doi=10.1002/14651858.CD011831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011831.pub2&amp;doi=10.1002/14651858.CD011831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011831.pub2&amp;doi=10.1002/14651858.CD011831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011831.pub2&amp;doi=10.1002/14651858.CD011831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="8ranHhTh";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011831\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011831\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011831\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011831\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","ms","hr","fr","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011831.pub2",title:"Chlorpromazine versus penfluridol for schizophrenia",firstPublishedDate:"Sep 23, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Schizophrenia Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=8ranHhTh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011831.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011831.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011831.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011831.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011831.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011831.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011831.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011831.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011831.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011831.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2100 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011831.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011831.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011831.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011831.pub2/full#CD011831-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011831.pub2/full#CD011831-sec-0191"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011831.pub2/full#CD011831-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011831.pub2/full#CD011831-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011831.pub2/full#CD011831-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011831.pub2/full#CD011831-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011831.pub2/full#CD011831-sec-0111"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011831.pub2/full#CD011831-sec-0173"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011831.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011831.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011831.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/table_n/CD011831StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/table_n/CD011831StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011831.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011831.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011831.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011831.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011831.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011831.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Chlorpromazine versus penfluridol for schizophrenia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011831.pub2/information#CD011831-cr-0002">Naemeh Nikvarz</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011831.pub2/information#CD011831-cr-0003">Mostafa Vahedian</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011831.pub2/information#CD011831-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Navid Khalili</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/information/en#CD011831-sec-0203">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 23 September 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011831.pub2">https://doi.org/10.1002/14651858.CD011831.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011831-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011831-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011831-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011831-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011831-abs-0002">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011831-abs-0013">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011831-abs-0001" lang="en"> <section id="CD011831-sec-0001"> <h3 class="title" id="CD011831-sec-0001">Background</h3> <p>The efficacy of chlorpromazine, a benchmark antipsychotic, has not been fully assessed in direct comparison with different individual antipsychotics. Penfluridol is another old antipsychotic with a long half‐life so one oral dose may last up to one week. This could confer advantage. </p> </section> <section id="CD011831-sec-0002"> <h3 class="title" id="CD011831-sec-0002">Objectives</h3> <p>To assess the clinical effects of chlorpromazine compared with penfluridol for adults with schizophrenia. </p> </section> <section id="CD011831-sec-0003"> <h3 class="title" id="CD011831-sec-0003">Search methods</h3> <p>On 31 March 2017, we searched the Cochrane Schizophrenia Group’s Study‐Based Register of Trials which is based on regular searches of CINAHL, BIOSIS, AMED, Embase, PubMed, MEDLINE, PsycINFO, and registries of clinical trials. There are no language, date, document type, or publication status limitations for inclusion of records in the register. </p> </section> <section id="CD011831-sec-0004"> <h3 class="title" id="CD011831-sec-0004">Selection criteria</h3> <p>We included all randomised clinical trials focusing on chlorpromazine versus penfluridol for adults with schizophrenia or related disorders. Outcomes of interest were death, service utilisation, global state, mental state, adverse effects and leaving the study early. We included trials meeting our selection criteria and reporting useable data. </p> </section> <section id="CD011831-sec-0005"> <h3 class="title" id="CD011831-sec-0005">Data collection and analysis</h3> <p>We extracted data independently. For binary outcomes, we calculated risk ratio (RR) and its 95% confidence interval (CI), on an intention‐to‐treat basis. For continuous data, we planned to estimate the mean difference (MD) between groups and its 95% CI. We employed a fixed‐effect model for analyses. We assessed risk of bias for included studies and created a 'Summary of findings' table using GRADE. </p> </section> <section id="CD011831-sec-0006"> <h3 class="title" id="CD011831-sec-0006">Main results</h3> <p>The review includes three studies with a total of 130 participants. Short‐term results for hospital admissions showed no clear difference between chlorpromazine and penfluridol (1 RCT, n = 29, RR 0.19, 95% CI 0.01 to 3.60, <i>low‐quality evidence</i> ). No clear difference in the incidence of akathisia was found at medium term (2 RCTs, n = 85, RR 0.19, 95% CI 0.04 to 1.06, <i>low‐quality evidence</i> ), and similar numbers of participants ‐ nearly half ‐ from each treatment group left the study early (3 RCTs, n = 130, RR 1.21, 95% CI 0.83 to 1.77, <i>low‐quality evidence</i>). The risk of needing additional antiparkinsonian medication was less in the chlorpromazine group (2 RCTs, n = 74, RR 0.70, 95% CI 0.51 to 0.95). No useable data reported clinically important change in global or mental state. No data were reported for relapse. No deaths were reported by the trials. </p> </section> <section id="CD011831-sec-0007"> <h3 class="title" id="CD011831-sec-0007">Authors' conclusions</h3> <p>Only three small studies provided data and the quality of reporting and evidence is low. Limited data indicate the efficacy and adverse effects profiles of chlorpromazine and penfluridol are generally similar. Penfluridol, however, may confer advantage by needing to be given only once per week. Firm conclusions are not possible without good‐quality trials, and where these treatments are used, such trials are justified. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011831-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011831-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD011831-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD011831-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011831-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011831-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD011831-abs-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011831-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011831-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011831-abs-0014">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011831-abs-0004" lang="en"> <h3>Chlorpromazine versus penfluridol for schizophrenia</h3> <p><b>Review question</b> </p> <p>How effective is the antipsychotic chlorpromazine as a treatment for schizophrenia compared to penfluridol? </p> <p><b>Background</b> </p> <p>Schizophrenia is serious mental disorder where people experience symptoms such as hallucinations and delusions, social withdrawal, decreased motivation and poor emotional response. The main treatment for schizophrenia is antipsychotic drugs. Chlorpromazine and penfluridol are widely used antipsychotics. However, different antipsychotics have different effects, and knowing the individual effects of different antipsychotics and what particular side effects they cause could help with deciding which antipsychotic to prescribe for an individual with schizophrenia. This review compares chlorpromazine with penfluridol and is one of a series of reviews comparing chlorpromazine directly with other antipsychotics. </p> <p><b>Searching</b> </p> <p>The Information Specialist of Cochrane Schizophrenia searched their trials register in March, 2017 for trials that randomised adults with schizophrenia or related disorders to receive either chlorpromazine or penfluridol. Seven records were found and checked by the review authors </p> <p><b>Evidence found</b> </p> <p>Only three randomised controlled trials, with a total of 130 participants met the review requirements and provided useable data. The quality of evidence available was low, no real difference was noted between chlorpromazine and penfluridol for hospital admissions, incidence of akathisia or numbers of participants leaving the study early. There were no deaths during the trials. We were unable to use the available data for global and mental state due to poor reporting, and no studies reported relapse data. </p> <p><b>Conclusions</b> </p> <p>We can not make firm conclusions regarding the comparable effectiveness between chlorpromazine and penfluridol with such poor quality data ‐ but penfluridol only needs to be given once per week ‐ which could help the poor adherence to medication common with schizophrenia. Remarkably, for such old drugs, more trials that report high‐quality data are needed. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011831-sec-0191" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011831-sec-0191"></div> <h3 class="title" id="CD011831-sec-0192">Implications for practice</h3> <section id="CD011831-sec-0192"> <section id="CD011831-sec-0193"> <h5 class="title">1. For people with schizophrenia</h5> <p>Although limited data on global state or mental state are available in the included studies of this review, there was no report that chlorpromazine was less effective than penfluridol regarding these outcomes. Needing supplementary antiparkinsonian drugs might be less with chlorpromazine in the medium term. </p> </section> <section id="CD011831-sec-0194"> <h5 class="title">2. For clinicians</h5> <p>There is the suggestion that chlorpromazine may cause less movement disorders than penfluridol, but data are too sparse to be sure. What very few data there are suggests little difference between the two drugs. Penfluridol, however, only needs to be given once per week. This is important and, if there were good data, this long half‐life could be useful for some people. </p> </section> <section id="CD011831-sec-0195"> <h5 class="title">3. For managers and policy makers</h5> <p>In situations where these two drugs are accessible, and prescribed, managers and policy makers may wish to encourage randomisation when there is clinical doubt as to which to use. In such a situation real‐world randomisation could add much to our knowledge of these drugs. </p> </section> </section> <h3 class="title" id="CD011831-sec-0196">Implications for research</h3> <section id="CD011831-sec-0196"> <section id="CD011831-sec-0197"> <h5 class="title">1. General</h5> <p>We had to exclude <a href="./references#CD011831-bbs2-0005" title="LiY . Application of NOSIE in the study of neuroleptic treatment. Chinese Journal of Neurology and Psychiatry1987;20(6):325‐7. [PUBMED: 3329087] ">Li 1987</a> due to the poor quality of data reporting, diminishing the already limited evidence‐base (please refer to <a href="./references#CD011831-sec-0210" title="">Characteristics of excluded studies</a> for details). Nowadays, following <a href="http://www.consort-statement.org/" target="_blank">CONSORT</a> (<a href="./references#CD011831-bbs2-0044" title="MoherD , SchulzKF , AltmanDG . The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials. BMC Medical Research Methodology2001;1:2. [PUBMED: 11336663] ">Moher 2001</a>) guidance for reporting of clinical trials would help increase the data available in this review. </p> </section> <section id="CD011831-sec-0198"> <h5 class="title">2. Specific</h5> <p>Even though chlorpromazine has been used in the management of schizophrenia for many years, and penfluridol is also an old drug, high‐quality evidence for comparative efficacy and safety is so limited that conducting a well‐designed large controlled study is justified where these treatments are still used. We do realise that such studies take meticulous planning but studies reporting clear and routine data have great utility and we suggest a design in <a href="#CD011831-tbl-0003">Table 2</a>. </p> <div class="table" id="CD011831-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Suggested design of study</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Methods</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised, fully explicit description of methods of randomisation and allocation concealment.<br/> Blinding: single‐blind or double‐blind, but tested.<br/> Setting: anywhere.<br/> Duration: follow‐up to at least 52 weeks. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diagnosis: schizophrenia.<br/> N = 300.*<br/> Age: adults.<br/> Sex: both. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Chlorpromazine: oral‐maximum around 400 mg/day. N = 150.</p> <p>2. Penfluridol: oral‐maximum around 80 mg/week. N = 150.</p> <p>Both groups could receive antiparkinsonian medication as required.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Service utilisation: Hospital admission, time to admission.</p> <p>Global state: Clinically significant response in global state, relapse.</p> <p>Mental state: Clinically significant response in mental state.</p> <p>Adverse effects: Clinically significant extrapyramidal side effects, death.</p> <p>Leaving the study early.</p> <p>Functioning: Employed, days working, in supportive relationship, healthy days.</p> <p>Economic outcomes.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Notes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>* Powered to be able to identify a difference of ˜ 20% between groups for primary outcome with adequate degree of certainty. </p> </td> </tr> </tbody> </table> </div> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011831-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011831-sec-0029"></div> <div class="table" id="CD011831-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Chlorpromazine versus Penfluridol for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> hospital inpatients and outpatients<br/> <b>Intervention:</b> Chlorpromazine versus penfluridol </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk<sup>3</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Penfluridol</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Chlorpromazine</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Service utilisation: hospital admission</b> (short term) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>150 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b> <br/> (1 to 540) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.19 (0.01 to 3.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low <sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: clinically important change in global state</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported 'clinically important change in global state'. Change in global state was measure using global state scales but all data were presented without SD. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: relapse</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: clinically important change in mental state</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported 'clinically important change in mental state'. Change in mental state was measure using mental state scales but all data were presented without SD. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effect/event: clinically important extrapyramidal adverse events ‐ akathisia</b> (medium term) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>38 per 1000</b> <br/> (8 to 212) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.19</b> </p> <p>(0.04 to 1.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85<br/> (2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low <sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The same studies reported data for other extrapyramidal adverse events such as rigidity, tremor, dystonia and dyskinesia. There was no observable difference between chlorpromazine and penfluridol regarding any of these adverse effects. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effect/event: death</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 RCTs</p> <p>(0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No deaths reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Leaving the study early: any reason</b> (medium term) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>484 per 1000</b> <br/> (332 to 708) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.21</b> </p> <p>(0.83 to 1.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130<br/> (3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low <sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> risk ratio; <b>SD:</b> standard deviation </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Serious risk of bias: downgraded by one level ‐ study had an unclear risk of bias for random sequence generation and blinding of assessors.<br/> <sup>2</sup> Serious risk of imprecision: downgraded by one level ‐ studies had small sample sizes and number of events.<br/> <sup>3</sup> We have used the risk of an event in the penfluridol group within the trial/s the benchmark, rounding to nearest five for clarity of presentation in the table. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011831-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011831-sec-0030"></div> <section id="CD011831-sec-0031"> <h3 class="title" id="CD011831-sec-0031">Description of the condition</h3> <p>Schizophrenia is a chronic disabling and relapsing mental illness with a worldwide lifetime prevalence of around 1% (<a href="./references#CD011831-bbs2-0009" title="Almeida‐FilhoN , Mari J deJ , CoutinhoE , FrancaJF , FernandesJ , AndreoliSB , et al. Brazilian multicentric study of psychiatric morbidity. Methodological features and prevalence estimates. British Journal of Psychiatry1997;171(6):524‐9. [PUBMED: 9519090] ">Almeida‐Filho 1997</a>; <a href="./references#CD011831-bbs2-0046" title="PeralaJ , SuvisaariJ , SaarniSI , KuoppasalmiK , IsometsaE , PirkolaS , et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Archives of General Psychiatry2007;64(1):19‐28. [PUBMED: 17199051] ">Perala 2007</a>). A person with schizophrenia experiences formal thought disorder and some cognitive disturbances (<a href="./references#CD011831-bbs2-0025" title="FioravantiM , CarloneO , VitaleB , CintiME , ClareL . A meta‐analysis of cognitive deficits in adults with a diagnosis of schizophrenia. Neuropsychology Review2005;15(2):73‐95. [PUBMED: 16211467] ">Fioravanti 2005</a>; <a href="./references#CD011831-bbs2-0040" title="LiddlePF . The symptoms of chronic schizophrenia. A re‐examination of the positive‐negative dichotomy. British Journal of Psychiatry1987;151:145‐51. [PUBMED: 3690102] ">Liddle 1987</a>). Symptoms can be divided into positive symptoms (such as delusions, hallucinations) and negative symptoms (such as poverty of speech, flattened affect, lack of pleasure, and lack of motivation) (<a href="./references#CD011831-bbs2-0016" title="CrowTJ . Molecular pathology of schizophrenia: more than one disease process?. British Medical Journal1980;280(6207):66‐8. [PUBMED: 6101544] ">Crow 1980</a>). Although the symptoms of schizophrenia can be treated with antipsychotic medication, people often relapse. One of the main reasons of relapse in schizophrenia is poor compliance to drugs, often due to their adverse effects, or lack of insight to the disorder (<a href="./references#CD011831-bbs2-0041" title="LindstromE , BingeforsK . Patient compliance with drug therapy in schizophrenia. Economic and clinical issues. PharmacoEconomics2000;18(2):106‐24. [PUBMED: 11067646] ">Lindstrom 2000</a>). </p> </section> <section id="CD011831-sec-0032"> <h3 class="title" id="CD011831-sec-0032">Description of the intervention</h3> <p>Antipsychotic drugs are the first‐line treatment for symptoms of schizophrenia. Chlorpromazine is one of the essential antipsychotic drugs in the World Health Organization's list of essential drugs (<a href="./references#CD011831-bbs2-0055" title="World Health Organization. 19th WHO Essential Medicines List. www.who.int/medicines/publications/essentialmedicines/en/ (accessed prior to 25 May 2017). ">WHO 2015</a>). Chlorpromazine was introduced in the 1950s for the treatment of both acute and chronic psychoses, including schizophrenia and the manic phase of bipolar disorder, as well as amphetamine‐induced psychoses. In early trials for schizophrenia, chlorpromazine in comparison with placebo showed efficacy in terms of clinical recovery, improvements in social functioning, and preventing relapse. Chlorpromazine has long been recognised as a benchmark by which other antipsychotics have been evaluated (<a href="./references#CD011831-bbs2-0007" title="AdamsCE , AwadGA , RathboneJ , ThornleyB , Soares‐WeiserK . Chlorpromazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews2014, Issue 1. [DOI: 10.1002/14651858.CD000284.pub3; PUBMED: 24395698] ">Adams 2014</a>). Chlorpromazine has a wide range of effects on various parts of the body; in addition to extrapyramidal side effects, it has anticholinergic and antihistaminergic effects which cause other adverse effects. To name a few, dry mouth, blurred vision, urinary retention, restlessness, tremors, facial rigidity, shuffling gait and repetitive movements of the face and/or trunk are some of its common side effects (<a href="./references#CD011831-bbs2-0007" title="AdamsCE , AwadGA , RathboneJ , ThornleyB , Soares‐WeiserK . Chlorpromazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews2014, Issue 1. [DOI: 10.1002/14651858.CD000284.pub3; PUBMED: 24395698] ">Adams 2014</a>). Chlorpromazine as a phenothiazine is the first of drugs named neuroleptics; after its discovery, new phenothiazine derivatives have also been introduced (<a href="./references#CD011831-bbs2-0047" title="ReesL . Chlorpromazine and allied phenothiazine derivatives. British Medical Journal1960;2(5197):522‐5. [PUBMED: 14436902] ">Rees 1960</a>). </p> <p>Penfluridol is a long‐acting antipsychotic agent first synthesised in 1963. This drug is usually administered once weekly and can be considered as a depot medication (<a href="./references#CD011831-bbs2-0027" title="GerlachJ , KrampP , KristjansenP , LauritsenB , LuhdorfK , MunkvadI . Peroral and parenteral administration of long‐acting neuroleptics: a double‐blind study of penfluridol compared to flupenthixol decanoate in the treatment of schizophrenia. Acta Psychiatrica Scandinavica1975;52(2):132‐44. [PUBMED: 1096541] ">Gerlach 1975</a>). It is a diphenylbutylpiperdine. Similar to chlorpromazine, the side effects of penfluridol are tardive dyskinesia, extrapyramidal symptoms and sedation (<a href="./references#CD011831-bbs2-0048" title="ReynoldsJEM . Penfluridol. Martindale: The Extra Pharmacopoeia. 28th Edition. London: The Pharmaceutical Press, 1982:1550. ">Reynolds 1982</a>). </p> </section> <section id="CD011831-sec-0033"> <h3 class="title" id="CD011831-sec-0033">How the intervention might work</h3> <p>Both chlorpromazine and penfluridol are typical antipsychotic drugs. Chlorpromazine is a phenothiazine [Subclass: aliphatic side chain; Formula: 2‐chloro‐10‐(3‐dimethylaminopropyl) phenothiazine] (<a href="#CD011831-fig-0001">Figure 1</a>). Trade names include Largactil, Hibernal, Megaphen, Solidon and Thorazine. Since it is a dopamine antagonist, its antipsychotic property affects particular areas of the brain. </p> <div class="figure" id="CD011831-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Chlorpromazine structure" data-id="CD011831-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_n/nCD011831-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Chlorpromazine structure</p> </div> </div> </div> <p>Penfluridol shows a relative antidopaminergic effect through the blocking of dopaminergic receptor membrane (<a href="./references#CD011831-bbs2-0027" title="GerlachJ , KrampP , KristjansenP , LauritsenB , LuhdorfK , MunkvadI . Peroral and parenteral administration of long‐acting neuroleptics: a double‐blind study of penfluridol compared to flupenthixol decanoate in the treatment of schizophrenia. Acta Psychiatrica Scandinavica1975;52(2):132‐44. [PUBMED: 1096541] ">Gerlach 1975</a>; <a href="./references#CD011831-bbs2-0034" title="JanssenPA , NiemegeersCJ , SchellekensKH , LenaertsFM , VerbruggenFJ , VanNuetenJM , et al. The pharmacology of penfluridol (R 16341) a new potent and orally long‐acting neuroleptic drug. European Journal of Pharmacology1970;11(2):139‐54. [PUBMED: 5447800] ">Janssen 1970</a>). It belongs to the diphenylbutylpiperidines (<a href="./references#CD011831-bbs2-0033" title="IonescuR , TiberiuC , MiklosR , AngelescuC , PersiceanuAM . Penfluridol in the maintenance therapy of schizophrenia. Neurologie et Psychiatrie1983;21(1):33‐41. [PUBMED: 6342112] ">Ionescu 1983</a>; <a href="./references#CD011831-bbs2-0054" title="vanPraagHM , SchutT , DolsL , vanSchilfgaardenR . Controlled trial of penfluridol in acute psychosis. British Medical Journal1971;4(5789):710‐3. [PUBMED: 4943034] ">van Praag 1971</a>) [Formula: 4‐(p‐chloro‐ ß‐trifluoro‐m‐tolyl)‐1‐[4,4‐bis(pfluorophenyl) butyl]‐4‐piperidinol] (<a href="#CD011831-fig-0002">Figure 2</a>). Trade names include Semap, Sémap and Flupidol. Pimozide is the other drug in this class. Penfluridol is a tertiary amine and only slightly soluble in water (<a href="./references#CD011831-bbs2-0034" title="JanssenPA , NiemegeersCJ , SchellekensKH , LenaertsFM , VerbruggenFJ , VanNuetenJM , et al. The pharmacology of penfluridol (R 16341) a new potent and orally long‐acting neuroleptic drug. European Journal of Pharmacology1970;11(2):139‐54. [PUBMED: 5447800] ">Janssen 1970</a>). After absorption from the gastrointestinal tract, it deposits in fatty tissue from which it is gradually released, giving the prolonged duration of effects of penfluridol with its 70 hour half‐life. </p> <div class="figure" id="CD011831-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Penfluridol structure" data-id="CD011831-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_n/nCD011831-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Penfluridol structure</p> </div> </div> </div> </section> <section id="CD011831-sec-0034"> <h3 class="title" id="CD011831-sec-0034">Why it is important to do this review</h3> <p>Chlorpromazine is widely used for psychotic disorders in Africa, India and South‐East Asia. Chlorpromazine is also usually a benchmark for evaluating other drugs (<a href="./references#CD011831-bbs2-0006" title="AdamsCE , RathboneJ , ThornleyB , ClarkeM , BorrillJ , WahlbeckK , et al. Chlorpromazine for schizophrenia: a Cochrane systematic review of 50 years of randomised controlled trials. BMC Medicine2005;3:15. [PUBMED: 16229742] ">Adams 2005</a>). This review is one of a series of reviews in order to evaluate chlorpromazine in comparison with other antipsychotics so that a full overview of chlorpromazine's clinical efficacy can be completed (<a href="#CD011831-tbl-0002">Table 1</a>). There is a Cochrane systematic review of <i>Penfluridol for schizophrenia</i> (<a href="./references#CD011831-bbs2-0051" title="SoaresBG , Silva de LimaM . Penfluridol for schizophrenia. Cochrane Database of Systematic Reviews2006, Issue 2. [DOI: 10.1002/14651858.CD002923.pub2; PUBMED: 16625563] ">Soares 2006</a>), however, the clinical profile of chlorpromazine compared with a long‐acting antipsychotic such as penfluridol needs to be updated. </p> <div class="table" id="CD011831-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Cochrane reviews on chlorpromazine for people with schizophrenia</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Review title</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reference</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acetophenazine versus chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011831-bbs2-0012" title="BazrafshanA , ZareM , OkhovatiM , Shamsi MeimandiM . Acetophenazine versus chlorpromazine for schizophrenia. Cochrane Database of Systematic Reviews2015, Issue 4. [DOI: 10.1002/14651858.CD011662] ">Bazrafshan 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine dose for people with schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011831-bbs2-0021" title="DudleyK , LiuX , DeHanS . Chlorpromazine dose for people with schizophrenia. Cochrane Database of Systematic Reviews2017, Issue 4. [DOI: 10.1002/14651858.CD007778.pub2; CD007778] ">Dudley 2009</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cessation of medication for people with schizophrenia already stable on chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011831-bbs2-0010" title="AlmerieMQ , AlkhateebH , EssaliA , MatarHE , RezkE . Cessation of medication for people with schizophrenia already stable on chlorpromazine. Cochrane Database of Systematic Reviews2007, Issue 1. [DOI: 10.1002/14651858.CD006329; CD006329] ">Almerie 2007</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus atypical antipsychotic drugs for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011831-bbs2-0049" title="SahaKB , BoL , ZhaoS , XiaJ , SampsonS , ZamanRU . Chlorpromazine versus atypical antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD010631.pub2] ">Saha 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus clotiapine for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Developing protocol</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus haloperidol for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011831-bbs2-0039" title="LeuchtC , KitzmantelM , KaneJ , LeuchtS , ChuaWLLC . Haloperidol versus chlorpromazine for schizophrenia. Cochrane Database of Systematic Reviews2008, Issue 1. [DOI: 10.1002/14651858.CD004278.pub2; CD004278] ">Leucht 2008</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus metiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011831-bbs2-0057" title="ZareM , BazrafshanA . Chlorpromazine versus metiapine for schizophrenia. Cochrane Database of Systematic Reviews2017, Issue 3. [DOI: 10.1002/14651858.CD011655.pub2] ">Zare 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus penfluridol for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Current review</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus piperacetazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011831-bbs2-0024" title="Eslami ShahrbabakiM , SharafkhaniR , DehnaviehR , ValiL . Chlorpromazine versus piperacetazine for schizophrenia. Cochrane Database of Systematic Reviews2015, Issue 6. [DOI: 10.1002/14651858.CD011709] ">Eslami 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus placebo for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011831-bbs2-0007" title="AdamsCE , AwadGA , RathboneJ , ThornleyB , Soares‐WeiserK . Chlorpromazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews2014, Issue 1. [DOI: 10.1002/14651858.CD000284.pub3; PUBMED: 24395698] ">Adams 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine for psychosis induced aggression or agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011831-bbs2-0008" title="AhmedU , JonesH , AdamsCE . Chlorpromazine for psychosis induced aggression or agitation. Cochrane Database of Systematic Reviews2010, Issue 4. [DOI: 10.1002/14651858.CD007445.pub2; CD007445] ">Ahmed 2010</a> </p> </td> </tr> </tbody> </table> </div> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011831-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011831-sec-0035"></div> <p>To assess the clinical effects of chlorpromazine compared with penfluridol for adults with schizophrenia. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011831-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011831-sec-0036"></div> <section id="CD011831-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011831-sec-0038"> <h4 class="title">Types of studies</h4> <p>We searched for all relevant randomised controlled trials. If a trial had been described as 'double‐blind' but implied randomisation, we planned to include such a trial in a sensitivity analysis ( see <a href="#CD011831-sec-0105">Sensitivity analysis</a>). We excluded quasi‐randomised studies, such as those allocating by alternate days of the week. Where people were given additional treatments within penfluridol prescription, we only included the data if the adjunct treatment was evenly distributed between groups and it was only the penfluridol that was randomised. </p> </section> <section id="CD011831-sec-0039"> <h4 class="title">Types of participants</h4> <p>Adults, however defined, with schizophrenia or related disorders, including schizophreniform disorder and schizoaffective disorder again, by any means of diagnosis. We are interested in making sure that information is as relevant to the current care of people with schizophrenia as possible so proposed, if information was available, to clearly highlight the current clinical state (acute, early post‐acute, partial remission, remission) as well as the stage (prodromal, first episode, early illness, persistent) and as to whether the studies primarily focused on people with particular problems (for example, negative symptoms, treatment‐resistant illnesses). </p> </section> <section id="CD011831-sec-0040"> <h4 class="title">Types of interventions</h4> <section id="CD011831-sec-0041"> <h5 class="title">1. Chlorpromazine</h5> <p>Any dose and mode or pattern of administration.</p> </section> <section id="CD011831-sec-0042"> <h5 class="title">2. Penfluridol</h5> <p>Any dose and mode or pattern of administration.</p> </section> </section> <section id="CD011831-sec-0043"> <h4 class="title">Types of outcome measures</h4> <p>We divided outcomes into short term (less than 12 weeks), medium term (12‐52 weeks) and long term (over one year). </p> <section id="CD011831-sec-0044"> <h5 class="title">Primary outcomes</h5> <section id="CD011831-sec-0045"> <h6 class="title">1. Service utilisation*</h6> <p>1.1 Hospital admission/readmission</p> </section> <section id="CD011831-sec-0046"> <h6 class="title">2. Global state</h6> <p>2.1 Clinically important change in global state ‐as defined by each of the studies (short term) </p> </section> <section id="CD011831-sec-0047"> <h6 class="title">3. Adverse effects</h6> <p>3.1 Clinically important extrapyramidal side effects ‐ as defined by each of the studies</p> </section> </section> <section id="CD011831-sec-0048"> <h5 class="title">Secondary outcomes</h5> <section id="CD011831-sec-0049"> <h6 class="title">1. Service utilisation</h6> <p>1.1 Days in hospital</p> </section> <section id="CD011831-sec-0050"> <h6 class="title">2. Global state</h6> <p>2.1 Average endpoint/change score on global state scale<br/> 2.2 Relapse ‐ as defined by each of the studies </p> </section> <section id="CD011831-sec-0051"> <h6 class="title">3. Mental state</h6> <p>3.1 Clinically important change in negative symptoms ‐ as defined by each of the studies<br/> 3.2 Average endpoint/change score on mental state scale<br/> 3.3 Average endpoint/change score in negative symptoms </p> </section> <section id="CD011831-sec-0052"> <h6 class="title">4. Behaviour</h6> <p>4.1 Clinically important change in behaviour ‐ as defined by each of the studies<br/> 4.2 Average endpoint/change score on behaviour scale </p> </section> <section id="CD011831-sec-0053"> <h6 class="title">5. Adverse effects/events</h6> <p>5.1 General<br/> 5.1.1. Death‐suicide/natural causes<br/> 5.1.2 At least one serious adverse effect/event </p> <p>5.2 Specific (grouped by system‐one expanded example given below)<br/> 5.2.1 Movement disorders<br/> a. Any extrapyramidal side effects<br/> b. Use of antiparkinson drugs<br/> c. Clinically important extrapyramidal side effects‐as defined by each of the studies<br/> d. Average endpoint/change score on extrapyramidal side effects scale </p> <p>5.2.2 Anticholinergic<br/> 5.2.3 Cardiovascular<br/> 5.2.4 Central nervous system<br/> 5.2.5 Gastrointestinal<br/> 5.2.6 Endocrine (e.g. amenorrhoea, galactorrhoea, hyperlipidaemia, hyperglycaemia, hyperinsulinaemia)<br/> 5.2.7 Haematology (e.g. haemogram, leucopenia, agranulocytosis/neutropenia)<br/> 5.2.8 Hepatic (e.g. abnormal transaminase, abnormal liver function)<br/> 5.2.9 Metabolic<br/> 5.2.10 Various other </p> </section> <section id="CD011831-sec-0054"> <h6 class="title">6. Leaving the study early</h6> <p>6.1 For any reason<br/> 6.2 Due to adverse effects </p> </section> <section id="CD011831-sec-0055"> <h6 class="title">7. Social functioning</h6> <p>7.1 Clinically important change in social functioning ‐as defined by each of the studies<br/> 7.2 Average endpoint/change score on social functioning scale<br/> 7.3 Employment status </p> </section> <section id="CD011831-sec-0056"> <h6 class="title">8. Economic outcomes</h6> </section> <section id="CD011831-sec-0057"> <h6 class="title">9. Quality of life/satisfaction with care, for either recipients of care or carers</h6> <p>9.1 Clinically important change in quality of life/satisfaction‐as defined by each of the studies<br/> 9.2 Average endpoint/change score on quality of life/satisfaction scale </p> </section> <section id="CD011831-sec-0058"> <h6 class="title">10. Cognitive functioning</h6> <p>10.1 Clinically important change in cognitive functioning ‐ as defined by each of the studies<br/> 10.2 Average endpoint/change score on cognitive functioning scale </p> <p>* see <a href="#CD011831-sec-0207">Differences between protocol and review</a> </p> </section> <section id="CD011831-sec-0059"> <h6 class="title">'Summary of findings' table</h6> <p>We used the GRADE approach to interpret findings (<a href="./references#CD011831-bbs2-0050" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In Higgins JPT, Green S editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011</a>); and used <a href="http://community.cochrane.org/tools/review-production-tools/gradepro-gdt" target="_blank">GRADEpro GDT</a> to export data from our review to create a 'Summary of findings' table . This table provides outcome‐specific information concerning the overall certainty of evidence from each included study in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on all outcomes we rate as important to patient care and decision making. We selected the following main outcomes for inclusion in the 'Summary of findings' table: </p> <p> <ol id="CD011831-list-0001"> <li> <p>Service utilisation: Hospital admission</p> </li> <li> <p>Global state: Clinically important change in global state‐as defined by each of the studies (short term) </p> </li> <li> <p>Global state: Relapse</p> </li> <li> <p>Mental state: Clinically important change in mental state ‐as defined by each of the studies (short term) </p> </li> <li> <p>Adverse effects: Clinically important extrapyramidal side effects ‐ as defined by each of the studies </p> </li> <li> <p>Adverse effects: Death</p> </li> <li> <p>Leaving the study early</p> </li> </ol> </p> </section> </section> </section> </section> <section id="CD011831-sec-0060"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011831-sec-0061"> <h4 class="title">Electronic searches</h4> <section id="CD011831-sec-0062"> <h5 class="title">Cochrane Schizophrenia Group’s Study‐Based Register of Trials</h5> <p>On 17 August 2015 and 31 March 2017, the Information Specialist searched the register using the following search strategy: </p> <p>(Chlorpromazine AND Penfluridol) in Intervention Field of STUDY</p> <p>In such a study‐based register, searching the major concept retrieves all the synonyms and relevant studies because all the studies have already been organised based on their interventions and linked to the relevant topics. </p> <p>This register is compiled by systematic searches of major resources (including AMED, BIOSIS, CINAHL, Embase, MEDLINE, PsycINFO, PubMed, and registries of clinical trials) and their monthly updates, handsearches, grey literature, and conference proceedings (see <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html" target="_blank">Group’s Module</a>). There is no language, date, document type, or publication status limitations for inclusion of records into the register. </p> </section> </section> <section id="CD011831-sec-0063"> <h4 class="title">Searching other resources</h4> <section id="CD011831-sec-0064"> <h5 class="title">1. Reference searching</h5> <p>We inspected the references of all included studies for further relevant studies.</p> </section> <section id="CD011831-sec-0065"> <h5 class="title">2. Personal contact</h5> <p>We did not contact the manufacturers of penfluridol or chlorpromazine for additional data. </p> </section> </section> </section> <section id="CD011831-sec-0066"> <h3 class="title" id="CD011831-sec-0066">Data collection and analysis</h3> <section id="CD011831-sec-0067"> <h4 class="title">Selection of studies</h4> <p>Review authors NN and NK independently inspected citations from the searches and identified relevant abstracts. MV independently re‐inspected a random 20% sample to ensure reliability. Where disputes arose, we acquired the full‐text report for more detailed scrutiny. NN and NK obtained and inspected the full reports of the abstracts meeting the review criteria. Again, MV re‐inspected a random 20% of reports in order to ensure reliable selection. If it had not been possible to resolve disagreement by discussion, we would have attempted to contact the authors of the study for clarification. </p> </section> <section id="CD011831-sec-0068"> <h4 class="title">Data extraction and management</h4> <section id="CD011831-sec-0069"> <h5 class="title">1. Extraction</h5> <p>Review author MV extracted data from all included studies. In addition, to ensure reliability, NN independently extracted data from all included studies. There were no disagreements between review authors in terms of the extracted data. If required, we would have extracted data presented only in graphs and figures whenever possible, but would have only included the data if two review authors independently had the same results. </p> </section> <section id="CD011831-sec-0070"> <h5 class="title">2. Management</h5> <section id="CD011831-sec-0071"> <h6 class="title">2.1 Forms</h6> <p>We extracted data onto standard, pre‐designed simple forms.</p> </section> <section id="CD011831-sec-0072"> <h6 class="title">2.2 Scale‐derived data</h6> <p>We would have included continuous data from rating scales only if:</p> <p> <ol id="CD011831-list-0002"> <li> <p>the psychometric properties of the measuring instrument have been described in a peer‐reviewed journal (<a href="./references#CD011831-bbs2-0043" title="MarshallM , LockwoodA , BradleyC , AdamsC , JoyC , FentonM . Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry2000;176:249‐52. ">Marshall 2000</a>); </p> </li> <li> <p>the measuring instrument has not been written or modified by one of the trialists for that particular trial; and </p> </li> <li> <p>the instrument should be a global assessment of an area of functioning and not sub‐scores which are not, in themselves, validated or shown to be reliable. However there are exceptions; we would have included sub‐scores from mental state scales measuring positive and negative symptoms of schizophrenia. </p> </li> </ol> </p> <p>Ideally, the measuring instrument should either be i. a self‐report or, ii. completed by an independent rater or relative (not the therapist). We realise that this is not often reported clearly; in 'Description of studies' in the Results section we would have noted whether or not this was the case. </p> </section> <section id="CD011831-sec-0073"> <h6 class="title">2.3 Endpoint versus change data</h6> <p>There are advantages to both endpoint and change data. Change data can remove a component of between‐person variability from the analysis. On the other hand, calculation of change needs two assessments (baseline and endpoint), which can be difficult in unstable and difficult to measure conditions such as schizophrenia. We decided primarily to use endpoint data, and only use change data if the former were not available. We would have combined endpoint and change data in the analysis as we prefer to use mean differences (MD) rather than standardised mean differences (SMD) (<a href="./references#CD011831-bbs2-0018" title="DeeksJJ , HigginsJPT , AltmanDG , editor(s) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Deeks 2011</a>). </p> </section> <section id="CD011831-sec-0074"> <h6 class="title">2.4 Skewed data</h6> <p>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non‐parametric data, we planned to apply the following standards to scale data. </p> <p><i>For endpoint data from studies N &lt; 200</i> </p> <p> <ol id="CD011831-list-0003"> <li> <p>If a scale started from the ﬁnite number zero, we would have subtracted the lowest possible value from the mean, and divided this by the standard deviation (SD). If this value was lower than 1, it would have strongly suggested a skew and we would have excluded such data. If this ratio was higher than 1 but below 2, there is a suggestion of skew. We would have entered such data and tested whether its inclusion or exclusion changed the results substantially. If these data did change the results we would have entered them as 'other data'. Finally, if the ratio was larger than 2, we would have included these data, because skew was less likely (<a href="./references#CD011831-bbs2-0011" title="AltmanDG , BlandJM . Detecting skewness from summary information. BMJ1996;313(7066):1200. ">Altman 1996</a>; <a href="./references#CD011831-bbs2-0030" title="HigginsJPT , GreenS , editor(s) . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Higgins 2011</a>). </p> </li> <li> <p>If a scale starts from a positive value (such as the Positive and Negative Syndrome Scale (PANSS), which can have values from 30 to 210) (<a href="./references#CD011831-bbs2-0035" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986. ">Kay 1986</a>), the calculation described above can be modified to take the scale starting point into account. In these cases skew is present if 2 SD &gt; (S‐S min), where S is the mean score and 'S min' is the minimum score. </p> </li> </ol> </p> <p><i>For change data</i> </p> <p> <ol id="CD011831-list-0004"> <li> <p>We would have entered change data as when continuous data are presented on a scale that includes a possibility of negative values (such as change data), it is difficult to tell whether data are skewed or not. We would have presented and entered change data into statistical analyses. </p> </li> </ol> </p> </section> <section id="CD011831-sec-0075"> <h6 class="title">2.5 Common measure</h6> <p>To facilitate comparison between trials, we intended to convert variables that can be reported in different metrics, such as days in hospital (mean days per year, per week, or per month) to a common metric (e.g. mean days per month). </p> </section> <section id="CD011831-sec-0076"> <h6 class="title">2.6 Conversion of continuous to binary</h6> <p>We would have made efforts to convert continuous outcome measures to dichotomous data. This can be done by identifying cut‐off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It is generally assumed that if there is a 50% reduction in a scale‐derived score such as the Brief Psychiatric Rating Scale (BPRS, <a href="./references#CD011831-bbs2-0045" title="OverallJE , GorhamDR . The brief psychiatric rating scale. Psychological Reports1962;10:799‐812. ">Overall 1962</a>) or the Positive and Negative Syndrome Scale (PANSS, <a href="./references#CD011831-bbs2-0035" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986. ">Kay 1986</a>), this could be considered as a clinically significant response (<a href="./references#CD011831-bbs2-0037" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelR . Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry2005;187:366‐71. [PUBMED: 16199797] ">Leucht 2005a</a>; <a href="./references#CD011831-bbs2-0038" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelRR . What does the PANSS mean?. Schizophrenia Research2005;79(2‐3):231‐8. [PUBMED: 15982856] ">Leucht 2005b</a>). Had data based on these thresholds not been available, we would have used the primary cut‐off presented by the original authors. </p> </section> <section id="CD011831-sec-0077"> <h6 class="title">2.7 Direction of graphs</h6> <p>Where possible, we entered data in such a way that the area to the left of the line of no effect indicates a favourable outcome for chlorpromazine. </p> </section> </section> </section> <section id="CD011831-sec-0078"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>MV and MV worked independently to assess risk of bias by using criteria described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011831-bbs2-0031" title="HigginsJPT , AltmanDG , SterneJAC , editor(s) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Higgins 2011a</a>) to assess trial quality. This set of criteria is based on evidence of associations between an overestimate of effect and high risk of bias of the article, such as sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting. </p> <p>If the raters had disagreed, the final rating would have been made by consensus. If inadequate details of randomisation and other characteristics of trials were provided, we would have contacted authors of the studies in order to obtain additional information. We would have reported non‐concurrence in quality assessment, and if disputes arose as to which category a trial was to be allocated, again, we would have resolved these by discussion. </p> <p>We noted the level of risk of bias both the <a href="./full#CD011831-sec-0111">Results</a> text of the review and in the <a href="./full#CD011831-tbl-0001">summary of findings Table for the main comparison</a> </p> </section> <section id="CD011831-sec-0079"> <h4 class="title">Measures of treatment effect</h4> <section id="CD011831-sec-0080"> <h5 class="title">1. Binary data</h5> <p>For binary outcomes, we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive (<a href="./references#CD011831-bbs2-0014" title="BoisselJP , CucheratM , LiW , ChatellierG , GueyffierF , BuyseM , et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie1999;54(4):405‐11. [PUBMED: 10667106] ">Boissel 1999</a>) than odds ratios (ORs) and that ORs tend to be interpreted as RRs by clinicians (<a href="./references#CD011831-bbs2-0017" title="DeeksJ . Issues in the selection for meta‐analyses of binary data. 8th International Cochrane Colloquium; 2000 Oct 25‐28; Cape Town. Cape Town: The Cochrane Collaboration, 2000. ">Deeks 2000</a>). The number needed to treat for an additional beneficial/harmful outcome (NNTB/NNTH) statistic with its CIs is intuitively attractive to clinicians, but is problematic both in its accurate calculation in meta‐analyses and interpretation (<a href="./references#CD011831-bbs2-0032" title="HuttonJL . Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology2009;146(1):27‐30. ">Hutton 2009</a>). For binary data presented in the 'Summary of findings' table, where possible, we calculated illustrative comparative risks. </p> </section> <section id="CD011831-sec-0081"> <h5 class="title">2. Continuous data</h5> <p>There were no usable reported continuous data in the included studies.</p> </section> </section> <section id="CD011831-sec-0082"> <h4 class="title">Unit of analysis issues</h4> <section id="CD011831-sec-0083"> <h5 class="title">1. Cluster trials</h5> <p>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice), but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intraclass correlation in clustered studies, leading to a 'unit of analysis' error (<a href="./references#CD011831-bbs2-0019" title="DivineGW , BrownJT , FrazierLM . The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine1992;7(6):623‐9. ">Divine 1992</a>) whereby P values are spuriously low, CIs unduly narrow, and statistical significance overestimated. This causes type I errors (<a href="./references#CD011831-bbs2-0013" title="BlandJM . Statistics notes. Trials randomised in clusters. BMJ1997;315:600. ">Bland 1997</a>; <a href="./references#CD011831-bbs2-0028" title="GullifordMC . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149:876‐83. ">Gulliford 1999</a>). </p> <p>If we had included cluster‐randomised trials and clustering had not been accounted for in primary studies, we would have presented data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review, we will seek to contact first authors of studies to obtain intra‐class correlation coefficients (ICCs) for their clustered data and adjust for this by using accepted methods (<a href="./references#CD011831-bbs2-0028" title="GullifordMC . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149:876‐83. ">Gulliford 1999</a>). If clustering had been incorporated into the analysis of primary studies, we would have presented these data as if from a non‐cluster randomised study, but adjusted the data for the clustering effect. </p> <p>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the ICC [Design effect=1+(m‐1)*ICC] (<a href="./references#CD011831-bbs2-0020" title="DonnerA , KlarN . Issues in the meta‐analysis of cluster randomized trials. Statistics in Medicine2002;21:2971‐80. ">Donner 2002</a>). If the ICC was not reported we would have assumed it to be 0.1 (<a href="./references#CD011831-bbs2-0053" title="UkoumunneOC , GullifordMC , ChinnS , SterneJAC , BurneyPGJ . Methods for evaluating area‐wide and organisation‐based intervention in health and health care: a systematic review. Health Technology Assessment1999;3(5):1‐75. ">Ukoumunne 1999</a>). </p> <p>If cluster studies have been appropriately analysed taking into account ICCs and relevant data documented in the report, synthesis with other studies would be possible using the generic inverse variance technique. </p> </section> <section id="CD011831-sec-0084"> <h5 class="title">2. Cross‐over trials</h5> <p>A major concern of cross‐over trials is the carry‐over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence, on entry to the second phase the participants can differ systematically from their initial state, despite a wash‐out phase. For the same reason, cross‐over trials are not appropriate if the condition of interest is unstable (<a href="./references#CD011831-bbs2-0023" title="ElbourneD , AltmanDG , HigginsJPT , CurtinaF , WorthingtonHV , VaileA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>). As both effects are very likely in severe mental illness, if cross‐over trials had been included, we would only have used data of the first phase of cross‐over studies. </p> </section> <section id="CD011831-sec-0085"> <h5 class="title">3. Studies with multiple treatment groups</h5> <p>Had a study involved more than two treatment arms, we would have presented the additional treatment arms in comparisons. If data were binary, we would simply have added and combined the data within the two‐by‐two table. If data were continuous, we would have combined data following the formula in section 7.7.3.8 (Combining groups) of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011831-bbs2-0030" title="HigginsJPT , GreenS , editor(s) . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Higgins 2011</a>). If the additional treatment arms were not relevant, we would not have used these data. </p> </section> </section> <section id="CD011831-sec-0086"> <h4 class="title">Dealing with missing data</h4> <section id="CD011831-sec-0087"> <h5 class="title">1. Overall loss of credibility</h5> <p>At some degree of loss of follow‐up, data must lose credibility (<a href="./references#CD011831-bbs2-0056" title="XiaJ , AdamsCE , BhagatN , BhagatV , BhoopathiP , El‐SayehH , et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin2009;33(7):254‐7. ">Xia 2009</a>). We chose that, for any particular outcome, should more than 50% of data be unaccounted for, we would not reproduce these data or use them within analyses. If, however, more than 50% of those in one arm of a study were lost, but the total loss was less than 50%, we would address this within the 'Summary of findings' table by down‐rating quality. Finally, we also planned to downgrade quality within the 'Summary of findings' table should the loss be 25% to 50% in total. </p> </section> <section id="CD011831-sec-0088"> <h5 class="title">2. Binary</h5> <p>In the case where attrition for a binary outcome was between 0% and 50% and where these data were not clearly described, we planned to present data on a 'once‐randomised‐always‐analyse' basis (an intention‐to‐treat analysis (ITT)). Those leaving the study early would all have been assumed to have the same rates of negative outcome as those who completed. We would have used the rate of those who stayed in the study ‐ in that particular arm of the trial ‐ and applied this also to those who did not. We planned to undertake a sensitivity analysis to test how prone the primary outcomes were to change when data only from people who completed the study to that point were compared to the intention‐to‐treat analysis using the above assumptions. </p> </section> <section id="CD011831-sec-0089"> <h5 class="title">3. Continuous</h5> <section id="CD011831-sec-0090"> <h6 class="title">3.1 Attrition</h6> <p>In cases where attrition for a continuous outcome was between 0% and 50%, and data only from people who completed the study to that point were reported, we would have reproduced such data. </p> </section> <section id="CD011831-sec-0091"> <h6 class="title">3.2 Standard deviations</h6> <p>If standard deviations (SDs) were not reported, we would first have tried to obtain the missing values from the authors. If not available, where there were missing measures of variance for continuous data, but an exact standard error (SE) and confidence intervals available for group means, and either a P value or t value available for differences in mean, we can calculate them according to the rules described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011831-bbs2-0030" title="HigginsJPT , GreenS , editor(s) . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Higgins 2011</a>): When only the SE is reported, SDs are calculated by the formula SD=SE * square root (n). Chapters 7.7.3 and 16.1.3 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011831-bbs2-0030" title="HigginsJPT , GreenS , editor(s) . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Higgins 2011</a>) present detailed formulae for estimating SDs from P values, t or F values, confidence intervals, ranges or other statistics. If these formulae do not apply, we can calculate the SDs according to a validated imputation method which is based on the SDs of the other included studies (<a href="./references#CD011831-bbs2-0026" title="FurukawaTA , BarbuiC , CiprianiA , BrambillaP , WatanabeN . Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology2006;59(7):7‐10. ">Furukawa 2006</a>). Although some of these imputation strategies can introduce error, the alternative would be to exclude a given study’s outcome and thus to lose information. We nevertheless would examine the validity of the imputations in a sensitivity analysis excluding imputed values. </p> </section> <section id="CD011831-sec-0092"> <h6 class="title">3.3 Assumptions about participants who left the trials early or were lost to follow‐up</h6> <p>Various methods are available to account for participants who leave the trials early or are lost to follow‐up. Some trials just present the results of study completers, others use the method of last observation carried forward (LOCF), while more recently methods such as multiple imputation or mixed effects models for repeated measurements (MMRM) have become more of a standard. While the latter methods seem to be somewhat better than LOCF (<a href="./references#CD011831-bbs2-0036" title="LeonAC , MallinckrodtCH , Chuang‐SteinC , ArchibaldDG , ArcherGE , ChartierK . Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biological Psychiatry2006;59(11):1001‐5. [PUBMED: 16905632] ">Leon 2006</a>), we feel that the high percentage of participants leaving the studies early and differences in the reasons for leaving the studies early between groups is often the core problem in randomised schizophrenia trials. We therefore decided we would not exclude studies based on the statistical approach used. However, we would preferably have used the more sophisticated approaches. For example, MMRM or multiple‐imputation is preferred to LOCF and we would only present completer analyses if some kind of ITT data were not available at all. Moreover, we addressed this issue in the 'Risk of bias' tool. </p> </section> </section> </section> <section id="CD011831-sec-0093"> <h4 class="title">Assessment of heterogeneity</h4> <section id="CD011831-sec-0094"> <h5 class="title">1. Clinical heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge clinical heterogeneity. We simply inspected all studies for clearly outlying people or situations which we had not predicted would arise. If such situations or participant groups had arisen, we would have discussed any issues. </p> </section> <section id="CD011831-sec-0095"> <h5 class="title">2. Methodological heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We simply inspected all studies for clearly outlying methods which we had not predicted would arise. If such methodological outliers had arisen, we would have discussed any issues. </p> </section> <section id="CD011831-sec-0096"> <h5 class="title">3. Statistical heterogeneity</h5> <p><b>3.1 Visual inspection</b> </p> <p>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</p> <p><b>3.2 Employing the I<sup>2</sup> statistic</b> </p> <p>We investigated heterogeneity between studies by considering the I<sup>2</sup> method alongside the Chi<sup>2</sup> P value. The I<sup>2</sup> provides an estimate of the percentage of inconsistency thought to be due to chance (<a href="./references#CD011831-bbs2-0029" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>). The importance of the observed value of I<sup>2</sup> depends on i. magnitude and direction of effects and ii. strength of evidence for heterogeneity (e.g. P value from Chi<sup>2</sup> test, or a confidence interval for I<sup>2</sup>). We would have considered an I<sup>2</sup> estimate greater than or equal to around 50% accompanied by a statistically significant Chi<sup>2</sup> statistic, as evidence of substantial levels of heterogeneity (Section 9.5.2, <a href="./references#CD011831-bbs2-0018" title="DeeksJJ , HigginsJPT , AltmanDG , editor(s) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Deeks 2011</a>). If substantial levels of heterogeneity had been found in the primary outcome, we would have explored reasons for heterogeneity (<a href="#CD011831-sec-0101">Subgroup analysis and investigation of heterogeneity</a>). </p> </section> </section> <section id="CD011831-sec-0097"> <h4 class="title">Assessment of reporting biases</h4> <p>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<a href="./references#CD011831-bbs2-0022" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315:629‐34. ">Egger 1997</a>). These are described in section 10.1 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011831-bbs2-0052" title="SterneJAC , EggerM , MoherD , editor(s) . Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Sterne 2011</a>). </p> <section id="CD011831-sec-0098"> <h5 class="title">1. Protocol versus full study</h5> <p>We tried to locate protocols of included randomised trials. If the protocol was available, we compared outcomes in the protocol and in the published report . If the protocol was not available, we compared outcomes listed in the methods section of the trial report with actually reported results. </p> </section> <section id="CD011831-sec-0099"> <h5 class="title">2. Funnel plot</h5> <p>We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small‐study effects. We planned not to use funnel plots for outcomes where there were 10 or fewer studies, or where all studies were of similar size. In other cases, where funnel plots were possible, we would have sought statistical advice in their interpretation. </p> </section> </section> <section id="CD011831-sec-0100"> <h4 class="title">Data synthesis</h4> <p>We understand that there is no closed argument for preference for use of fixed‐effect or random‐effects models. The random‐effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This often seems to be true to us and the random‐effects model takes into account differences between studies even if there is no statistically significant heterogeneity. There is, however, a disadvantage to the random‐effects model. It puts added weight onto small studies which often are the most biased ones. Depending on the direction of effect these studies can either inflate or deflate the effect size. We chose fixed model for all analyses. </p> </section> <section id="CD011831-sec-0101"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <section id="CD011831-sec-0102"> <h5 class="title">1. Subgroup analyses</h5> <section id="CD011831-sec-0103"> <h6 class="title">1.1 Primary outcomes</h6> <p>No subgroup analysis was anticipated.</p> </section> </section> <section id="CD011831-sec-0104"> <h5 class="title">2. Investigation of heterogeneity</h5> <p>If inconsistency was high, we would have reported it. First, we would have investigated whether data had been entered correctly. Second, if data were correct, we would have visually inspected the graph and successively removed outlying studies to see if homogeneity was restored. For this review, we decided that should this occur with data contributing to the summary finding of no more than around 10% of the total weighting, we would present the data. If not, we would not pool these data, but discuss any issues. We know of no supporting research for this 10% cut‐off but are investigating use of prediction intervals as an alternative to this unsatisfactory state. </p> <p>If unanticipated clinical or methodological heterogeneity had been obvious we would simply have stated hypotheses regarding these for future reviews or versions of this review. We did not anticipate undertaking analyses relating to these. </p> </section> </section> <section id="CD011831-sec-0105"> <h4 class="title">Sensitivity analysis</h4> <p>If substantial differences had been noted in the direction or precision of effect estimates in any of the sensitivity analyses listed below, we would not have pooled data from the excluded trials with the other trials contributing to the outcome, but presented them separately as 'other data'. </p> <section id="CD011831-sec-0106"> <h5 class="title">1. Implication of randomisation</h5> <p>We would have included trials in a sensitivity analysis if they had been described in some way as to imply randomisation. For the primary outcomes, if there had been no substantive difference when we added the implied randomised studies to those with better descriptions of randomisation, then we would have employed all data from these studies. </p> </section> <section id="CD011831-sec-0107"> <h5 class="title">2. Assumptions for lost binary data</h5> <p>Where assumptions had to be made regarding people lost to follow‐up (see <a href="#CD011831-sec-0086">Dealing with missing data</a>), we would have compared the findings of the primary outcomes when we used our assumptions and when we used data only from people who completed the study to that point. If there was a substantial difference, we would have reported results and discussed them but continued to employ our assumption. </p> </section> <section id="CD011831-sec-0108"> <h5 class="title">3. Risk of bias</h5> <p>For the primary outcome, we would have analysed the effects of excluding trials that were judged to be at high risk of bias across one or more of the domains of randomisation (see <a href="#CD011831-sec-0078">Assessment of risk of bias in included studies</a>). If the exclusion of trials at high risk of bias had not substantially altered the direction of effect or the precision of the effect estimates, then we would have included data from these trials in the analysis. </p> </section> <section id="CD011831-sec-0109"> <h5 class="title">4. Imputed values</h5> <p>If we had included cluster trials, we would have undertaken a sensitivity analysis to assess the effects of including data from trials where we used imputed values for ICC in calculating the design effect in cluster‐randomised trials. </p> </section> <section id="CD011831-sec-0110"> <h5 class="title">5. Fixed‐effect or random‐effects</h5> <p>We synthesised all data using a fixed‐effect model. However, we also synthesised data for the primary outcome using a random‐effects model to evaluate whether this altered the significance of the results. If there had been a substantial difference, we would have reported this. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011831-sec-0111" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011831-sec-0111"></div> <section id="CD011831-sec-0112"> <h3 class="title">Description of studies</h3> <p>Please see <a href="./references#CD011831-sec-0209" title="">Characteristics of included studies</a> and <a href="./references#CD011831-sec-0210" title="">Characteristics of excluded studies</a>. </p> <section id="CD011831-sec-0113"> <h4 class="title">Results of the search</h4> <p>Details of the search results are illustrated in the PRISMA table (<a href="#CD011831-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD011831-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD011831-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_n/nCD011831-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>In the original search we found seven reports that were potentially relevant. There were no duplicates. We inspected full text of these reports and then grouped these into trials where several reports referred to the same trial. After excluding two trials, we included three trials (five reports). </p> </section> <section id="CD011831-sec-0114"> <h4 class="title">Included studies</h4> <section id="CD011831-sec-0115"> <h5 class="title">1. Duration</h5> <p>Duration of studies ranged from 13 to 52 weeks. Results of <a href="./references#CD011831-bbs2-0001" title="ChouinardG , AnnableL . Penfluridol in the treatment of newly admitted schizophrenic patients in a brief therapy unit. American Journal of Psychiatry1976;133(7):850‐3. [PUBMED: 937582] ChouinardG , AnnableL , CooperS . Antiparkinsonian drug administration and plasma levels of penfluridol, a new long‐acting neuroleptic. Communications in Psychopharmacology1977;1(4):325‐31. [PUBMED: 615695] ChouinardG , AnnableL , KolivakisTN . Penfluridol in the maintenance treatment of schizophrenic patients newly discharged from a brief therapy unit. Journal of Clinical Pharmacology1977;17(2‐3):162‐7. [PUBMED: 833344] ">Chouinard 1977</a> were reported in three separate published articles. Two of them contain results of participants receiving the chlorpromazine or penfluridol for an inpatient phase of three weeks and the other has results of an outpatient follow‐up phase which lasted 10 weeks. <a href="./references#CD011831-bbs2-0003" title="WangRI , LarsonC , TreulSJ . Study of penfluridol and chlorpromazine in the treatment of chronic schizophrenia. Journal of Clinical Pharmacology1982;22(5‐6):236‐42. [PUBMED: 7107969] ">Wang 1982</a> was a medium‐term trial of 20 weeks and, finally, <a href="./references#CD011831-bbs2-0002" title="ClaghornJL , MathewRJ , MirabiM . Penfluridol: a long acting oral antipsychotic drug. Journal of Clinical Psychiatry1979;40(2):107‐9. [PUBMED: 368045] ">Claghorn 1979</a> was for a total of 52 weeks. </p> </section> <section id="CD011831-sec-0116"> <h5 class="title">2. Participants</h5> <p>A total of 130 people aged 19 to 60 years participated in the studies.</p> <p>All participants were diagnosed with schizophrenia. Participants in <a href="./references#CD011831-bbs2-0001" title="ChouinardG , AnnableL . Penfluridol in the treatment of newly admitted schizophrenic patients in a brief therapy unit. American Journal of Psychiatry1976;133(7):850‐3. [PUBMED: 937582] ChouinardG , AnnableL , CooperS . Antiparkinsonian drug administration and plasma levels of penfluridol, a new long‐acting neuroleptic. Communications in Psychopharmacology1977;1(4):325‐31. [PUBMED: 615695] ChouinardG , AnnableL , KolivakisTN . Penfluridol in the maintenance treatment of schizophrenic patients newly discharged from a brief therapy unit. Journal of Clinical Pharmacology1977;17(2‐3):162‐7. [PUBMED: 833344] ">Chouinard 1977</a> were classified as paranoid or non‐paranoid subtype based on the Diagnostic and Statistical Manual of Mental Disorders_II (DSM‐II criteria). <a href="./references#CD011831-bbs2-0003" title="WangRI , LarsonC , TreulSJ . Study of penfluridol and chlorpromazine in the treatment of chronic schizophrenia. Journal of Clinical Pharmacology1982;22(5‐6):236‐42. [PUBMED: 7107969] ">Wang 1982</a> reported no criteria for diagnosis of schizophrenia. The diagnostic criteria for <a href="./references#CD011831-bbs2-0002" title="ClaghornJL , MathewRJ , MirabiM . Penfluridol: a long acting oral antipsychotic drug. Journal of Clinical Psychiatry1979;40(2):107‐9. [PUBMED: 368045] ">Claghorn 1979</a> are not clear. All participants had a history of chronic schizophrenia with the people in the <a href="./references#CD011831-bbs2-0002" title="ClaghornJL , MathewRJ , MirabiM . Penfluridol: a long acting oral antipsychotic drug. Journal of Clinical Psychiatry1979;40(2):107‐9. [PUBMED: 368045] ">Claghorn 1979</a> study being particularly unwell with a duration of illness in the decades and even the particular episode of illness being between eight and 10 years long. </p> <p>Participants in <a href="./references#CD011831-bbs2-0003" title="WangRI , LarsonC , TreulSJ . Study of penfluridol and chlorpromazine in the treatment of chronic schizophrenia. Journal of Clinical Pharmacology1982;22(5‐6):236‐42. [PUBMED: 7107969] ">Wang 1982</a> were all males. <a href="./references#CD011831-bbs2-0002" title="ClaghornJL , MathewRJ , MirabiM . Penfluridol: a long acting oral antipsychotic drug. Journal of Clinical Psychiatry1979;40(2):107‐9. [PUBMED: 368045] ">Claghorn 1979</a> and <a href="./references#CD011831-bbs2-0001" title="ChouinardG , AnnableL . Penfluridol in the treatment of newly admitted schizophrenic patients in a brief therapy unit. American Journal of Psychiatry1976;133(7):850‐3. [PUBMED: 937582] ChouinardG , AnnableL , CooperS . Antiparkinsonian drug administration and plasma levels of penfluridol, a new long‐acting neuroleptic. Communications in Psychopharmacology1977;1(4):325‐31. [PUBMED: 615695] ChouinardG , AnnableL , KolivakisTN . Penfluridol in the maintenance treatment of schizophrenic patients newly discharged from a brief therapy unit. Journal of Clinical Pharmacology1977;17(2‐3):162‐7. [PUBMED: 833344] ">Chouinard 1977</a> included both men and women. </p> </section> <section id="CD011831-sec-0117"> <h5 class="title">3. Setting</h5> <p><a href="./references#CD011831-bbs2-0001" title="ChouinardG , AnnableL . Penfluridol in the treatment of newly admitted schizophrenic patients in a brief therapy unit. American Journal of Psychiatry1976;133(7):850‐3. [PUBMED: 937582] ChouinardG , AnnableL , CooperS . Antiparkinsonian drug administration and plasma levels of penfluridol, a new long‐acting neuroleptic. Communications in Psychopharmacology1977;1(4):325‐31. [PUBMED: 615695] ChouinardG , AnnableL , KolivakisTN . Penfluridol in the maintenance treatment of schizophrenic patients newly discharged from a brief therapy unit. Journal of Clinical Pharmacology1977;17(2‐3):162‐7. [PUBMED: 833344] ">Chouinard 1977</a> had an inpatient setting for three weeks, followed by a 10‐week outpatient phase. <a href="./references#CD011831-bbs2-0003" title="WangRI , LarsonC , TreulSJ . Study of penfluridol and chlorpromazine in the treatment of chronic schizophrenia. Journal of Clinical Pharmacology1982;22(5‐6):236‐42. [PUBMED: 7107969] ">Wang 1982</a> included both inpatients and outpatients. <a href="./references#CD011831-bbs2-0002" title="ClaghornJL , MathewRJ , MirabiM . Penfluridol: a long acting oral antipsychotic drug. Journal of Clinical Psychiatry1979;40(2):107‐9. [PUBMED: 368045] ">Claghorn 1979</a>, dealing with a group of very ill people, was conducted all in hospital. </p> </section> <section id="CD011831-sec-0118"> <h5 class="title">4. Intervention</h5> <p>Both intervention drugs were administered orally.</p> <section id="CD011831-sec-0119"> <h6 class="title">4.1 Chlorpromazine</h6> <p>The starting dose and maximum doses of chlorpromazine in <a href="./references#CD011831-bbs2-0003" title="WangRI , LarsonC , TreulSJ . Study of penfluridol and chlorpromazine in the treatment of chronic schizophrenia. Journal of Clinical Pharmacology1982;22(5‐6):236‐42. [PUBMED: 7107969] ">Wang 1982</a> were 415 mg/day and 1050 mg/day, respectively. <a href="./references#CD011831-bbs2-0001" title="ChouinardG , AnnableL . Penfluridol in the treatment of newly admitted schizophrenic patients in a brief therapy unit. American Journal of Psychiatry1976;133(7):850‐3. [PUBMED: 937582] ChouinardG , AnnableL , CooperS . Antiparkinsonian drug administration and plasma levels of penfluridol, a new long‐acting neuroleptic. Communications in Psychopharmacology1977;1(4):325‐31. [PUBMED: 615695] ChouinardG , AnnableL , KolivakisTN . Penfluridol in the maintenance treatment of schizophrenic patients newly discharged from a brief therapy unit. Journal of Clinical Pharmacology1977;17(2‐3):162‐7. [PUBMED: 833344] ">Chouinard 1977</a> prescribed chlorpromazine at dose of 300 mg/day during the first week, 600 mg/day in the second week and 900 mg/day during the third week, and continued the last dose in the 10‐week follow‐up phase (the mean dose was 650 mg/day). Although there were higher doses used, the final mean dose in <a href="./references#CD011831-bbs2-0002" title="ClaghornJL , MathewRJ , MirabiM . Penfluridol: a long acting oral antipsychotic drug. Journal of Clinical Psychiatry1979;40(2):107‐9. [PUBMED: 368045] ">Claghorn 1979</a> settled at 300 mg/day. </p> </section> <section id="CD011831-sec-0120"> <h6 class="title">4.2 Penfluridol</h6> <p>The initial dose, and maximum doses of penfluridol <a href="./references#CD011831-bbs2-0003" title="WangRI , LarsonC , TreulSJ . Study of penfluridol and chlorpromazine in the treatment of chronic schizophrenia. Journal of Clinical Pharmacology1982;22(5‐6):236‐42. [PUBMED: 7107969] ">Wang 1982</a> were 60 mg/week and 140 mg/week, respectively. <a href="./references#CD011831-bbs2-0001" title="ChouinardG , AnnableL . Penfluridol in the treatment of newly admitted schizophrenic patients in a brief therapy unit. American Journal of Psychiatry1976;133(7):850‐3. [PUBMED: 937582] ChouinardG , AnnableL , CooperS . Antiparkinsonian drug administration and plasma levels of penfluridol, a new long‐acting neuroleptic. Communications in Psychopharmacology1977;1(4):325‐31. [PUBMED: 615695] ChouinardG , AnnableL , KolivakisTN . Penfluridol in the maintenance treatment of schizophrenic patients newly discharged from a brief therapy unit. Journal of Clinical Pharmacology1977;17(2‐3):162‐7. [PUBMED: 833344] ">Chouinard 1977</a> prescribed penfluridol at single dose of 40 mg in the first week, 80 mg in the second week and 120 mg during the third week and continued the last dose in the 10‐week follow‐up phase (the mean dose was 102 mg/week). A similar regimen was adopted by <a href="./references#CD011831-bbs2-0002" title="ClaghornJL , MathewRJ , MirabiM . Penfluridol: a long acting oral antipsychotic drug. Journal of Clinical Psychiatry1979;40(2):107‐9. [PUBMED: 368045] ">Claghorn 1979</a>, with the final mean dose being 74 mg/week. </p> </section> </section> <section id="CD011831-sec-0121"> <h5 class="title">5. Outcomes and outcome scales</h5> <p>Studies reported dichotomous (binary) and continuous outcomes; however, all scale data were impossible to use as, either, means were presented without SD or attrition was over 50% (please see <a href="#CD011831-sec-0086">Dealing with missing data</a>). No included study reported economic outcomes, and effects of interventions on quality of life, employment status or cognitive functioning. </p> </section> </section> <section id="CD011831-sec-0122"> <h4 class="title">Excluded studies</h4> <p>We excluded two studies. One was a quasi‐randomised study (<a href="./references#CD011831-bbs2-0004" title="BaoXQ . A double‐blind study on the effect of clozapine, penfluridol and chlorpromazine in the treatment of schizophrenia. Chinese Journal of Neurology and Psychiatry1988;21(5):274‐6, 318. [PUBMED: 3069382] ">Bao 1988</a>). We initially had excluded <a href="./references#CD011831-bbs2-0002" title="ClaghornJL , MathewRJ , MirabiM . Penfluridol: a long acting oral antipsychotic drug. Journal of Clinical Psychiatry1979;40(2):107‐9. [PUBMED: 368045] ">Claghorn 1979</a> as less than 50% of people completed the entire course of the trial, but found that some adverse effects and the number actually leaving were reported on 100% of people; as a result, this study is now included. <a href="./references#CD011831-bbs2-0005" title="LiY . Application of NOSIE in the study of neuroleptic treatment. Chinese Journal of Neurology and Psychiatry1987;20(6):325‐7. [PUBMED: 3329087] ">Li 1987</a> also seemed to have high attrition, but in addition, the number of people in each group was not mentioned. Therefore we excluded this study. </p> </section> </section> <section id="CD011831-sec-0123"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD011831-fig-0004">Figure 4</a> and <a href="#CD011831-fig-0005">Figure 5</a> . </p> <div class="figure" id="CD011831-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011831-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_n/nCD011831-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD011831-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011831-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_n/nCD011831-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD011831-sec-0124"> <h4 class="title">Allocation</h4> <p>None of the included studies described the methods used to generate random allocation, although <a href="./references#CD011831-bbs2-0002" title="ClaghornJL , MathewRJ , MirabiM . Penfluridol: a long acting oral antipsychotic drug. Journal of Clinical Psychiatry1979;40(2):107‐9. [PUBMED: 368045] ">Claghorn 1979</a> used block randomisation. Having said that, the <a href="./references#CD011831-bbs2-0002" title="ClaghornJL , MathewRJ , MirabiM . Penfluridol: a long acting oral antipsychotic drug. Journal of Clinical Psychiatry1979;40(2):107‐9. [PUBMED: 368045] ">Claghorn 1979</a> study, conscious of how allocation can still result in imbalanced groups, reported on differences in distribution of illness duration and sex. There was an implication from the writing in this study that the authors understood the randomisation procedure. We have no information from these old studies about allocation concealment. </p> </section> <section id="CD011831-sec-0125"> <h4 class="title">Blinding</h4> <p>All three included trials used a double‐blind design. <a href="./references#CD011831-bbs2-0001" title="ChouinardG , AnnableL . Penfluridol in the treatment of newly admitted schizophrenic patients in a brief therapy unit. American Journal of Psychiatry1976;133(7):850‐3. [PUBMED: 937582] ChouinardG , AnnableL , CooperS . Antiparkinsonian drug administration and plasma levels of penfluridol, a new long‐acting neuroleptic. Communications in Psychopharmacology1977;1(4):325‐31. [PUBMED: 615695] ChouinardG , AnnableL , KolivakisTN . Penfluridol in the maintenance treatment of schizophrenic patients newly discharged from a brief therapy unit. Journal of Clinical Pharmacology1977;17(2‐3):162‐7. [PUBMED: 833344] ">Chouinard 1977</a> had an unclear risk of bias as reports did not explain how they used a double‐blind method and how successful their attempts at blinding were. <a href="./references#CD011831-bbs2-0002" title="ClaghornJL , MathewRJ , MirabiM . Penfluridol: a long acting oral antipsychotic drug. Journal of Clinical Psychiatry1979;40(2):107‐9. [PUBMED: 368045] ">Claghorn 1979</a> used placebo tablets to mask that participants in one group really only got one active dose per week whereas those allocated to chlorpromazine were given active compound daily. <a href="./references#CD011831-bbs2-0003" title="WangRI , LarsonC , TreulSJ . Study of penfluridol and chlorpromazine in the treatment of chronic schizophrenia. Journal of Clinical Pharmacology1982;22(5‐6):236‐42. [PUBMED: 7107969] ">Wang 1982</a> described their method of blinding. In this study all patients received identical appearing capsules on a special "blister pack" medication card allowing the patient to take the medication on a twice‐a‐day schedule. We rated <a href="./references#CD011831-bbs2-0003" title="WangRI , LarsonC , TreulSJ . Study of penfluridol and chlorpromazine in the treatment of chronic schizophrenia. Journal of Clinical Pharmacology1982;22(5‐6):236‐42. [PUBMED: 7107969] ">Wang 1982</a> as low risk of bias for performance bias as they had described the methods used to ensure blinding of participants and personnel. </p> </section> <section id="CD011831-sec-0126"> <h4 class="title">Incomplete outcome data</h4> <p>This was not a major issue in two of the trials. <a href="./references#CD011831-bbs2-0002" title="ClaghornJL , MathewRJ , MirabiM . Penfluridol: a long acting oral antipsychotic drug. Journal of Clinical Psychiatry1979;40(2):107‐9. [PUBMED: 368045] ">Claghorn 1979</a>, however, had high attrition that was clearly described. </p> </section> <section id="CD011831-sec-0127"> <h4 class="title">Selective reporting</h4> <p>We felt that both <a href="./references#CD011831-bbs2-0001" title="ChouinardG , AnnableL . Penfluridol in the treatment of newly admitted schizophrenic patients in a brief therapy unit. American Journal of Psychiatry1976;133(7):850‐3. [PUBMED: 937582] ChouinardG , AnnableL , CooperS . Antiparkinsonian drug administration and plasma levels of penfluridol, a new long‐acting neuroleptic. Communications in Psychopharmacology1977;1(4):325‐31. [PUBMED: 615695] ChouinardG , AnnableL , KolivakisTN . Penfluridol in the maintenance treatment of schizophrenic patients newly discharged from a brief therapy unit. Journal of Clinical Pharmacology1977;17(2‐3):162‐7. [PUBMED: 833344] ">Chouinard 1977</a> and <a href="./references#CD011831-bbs2-0003" title="WangRI , LarsonC , TreulSJ . Study of penfluridol and chlorpromazine in the treatment of chronic schizophrenia. Journal of Clinical Pharmacology1982;22(5‐6):236‐42. [PUBMED: 7107969] ">Wang 1982</a> carry at least an 'unclear' risk of bias for selective reporting as quite a few outcomes were not clearly reported. <a href="./references#CD011831-bbs2-0002" title="ClaghornJL , MathewRJ , MirabiM . Penfluridol: a long acting oral antipsychotic drug. Journal of Clinical Psychiatry1979;40(2):107‐9. [PUBMED: 368045] ">Claghorn 1979</a>, however, we thought, should be rated as 'high' risk as there was clear selective reporting of adverse effects. We recognise that when extensive investigations are undertaken this can generate a very long list of rare adverse effects that is cumbersome to reproduce in the published report. With online storage of data this becomes less of a problem and we may be judging <a href="./references#CD011831-bbs2-0002" title="ClaghornJL , MathewRJ , MirabiM . Penfluridol: a long acting oral antipsychotic drug. Journal of Clinical Psychiatry1979;40(2):107‐9. [PUBMED: 368045] ">Claghorn 1979</a> by standards of three decades beyond its publication. However, we think, even in 1979, inclusion of extensive lists of adverse effects was not rare and such a table would have been reassuring to the reader that rare but important effects had not been under‐reported. </p> </section> <section id="CD011831-sec-0128"> <h4 class="title">Other potential sources of bias</h4> <p>All three studies had an unclear risk of bias for other potential sources of bias.</p> </section> </section> <section id="CD011831-sec-0129"> <h3 class="title" id="CD011831-sec-0129">Effects of interventions</h3> <p>See: <a href="./full#CD011831-tbl-0001"><b>Summary of findings for the main comparison</b> </a> </p> <section id="CD011831-sec-0130"> <h4 class="title">1. COMPARISON 1. Chlorpromazine versus penfluridol</h4> <section id="CD011831-sec-0131"> <h5 class="title">1. Service utilisation: hospital readmission</h5> <p>We identified one short‐term study (n = 29) reporting data for this outcome. We did not find evidence of a clear difference between chlorpromazine and penfluridol (risk ratio (RR) 0.19, 95% confidence interval (CI) 0.01 to 3.60, low‐quality evidence; <a href="./references#CD011831-fig-0006" title="">Analysis 1.1</a>). </p> </section> <section id="CD011831-sec-0132"> <h5 class="title">1.2 Adverse effects: 1a. General ‐ needing antiparkinsonian medication</h5> <p>Short‐term results from <a href="./references#CD011831-bbs2-0001" title="ChouinardG , AnnableL . Penfluridol in the treatment of newly admitted schizophrenic patients in a brief therapy unit. American Journal of Psychiatry1976;133(7):850‐3. [PUBMED: 937582] ChouinardG , AnnableL , CooperS . Antiparkinsonian drug administration and plasma levels of penfluridol, a new long‐acting neuroleptic. Communications in Psychopharmacology1977;1(4):325‐31. [PUBMED: 615695] ChouinardG , AnnableL , KolivakisTN . Penfluridol in the maintenance treatment of schizophrenic patients newly discharged from a brief therapy unit. Journal of Clinical Pharmacology1977;17(2‐3):162‐7. [PUBMED: 833344] ">Chouinard 1977</a> showed no observable difference between chlorpromazine and penfluridol for numbers of participants needing antiparkinsonian medication (1 RCT, n = 33, RR 0.82, 95% CI 0.46 to 1.46) and <a href="./references#CD011831-bbs2-0003" title="WangRI , LarsonC , TreulSJ . Study of penfluridol and chlorpromazine in the treatment of chronic schizophrenia. Journal of Clinical Pharmacology1982;22(5‐6):236‐42. [PUBMED: 7107969] ">Wang 1982</a> however found evidence that chlorpromazine had a favourable effect in the medium term (1 RCT, n = 41, RR 0.63, 95% CI 0.43 to 0.91). Overall, there was suggestion that use of chlorpromazine carried less risk of needing additional medication for movement disorder adverse effects (2 RCTs, n = 74, RR 0.70, 95% CI 0.51 to 0.95; <a href="./references#CD011831-fig-0007" title="">Analysis 1.2</a>). </p> </section> <section id="CD011831-sec-0133"> <h5 class="title">1.3 Adverse effects: 1b. General ‐ need to reduce antipsychotic dose due to adverse effects </h5> <p>Similar numbers of participants from each group needed a reduction in their antipsychotic dose to alleviate adverse effects (1 RCT, n = 33, RR 0.74, 95% CI 0.26 to 2.06; <a href="./references#CD011831-fig-0008" title="">Analysis 1.3</a>). </p> </section> <section id="CD011831-sec-0134"> <h5 class="title">1.4 Adverse effects: 2a. Specific ‐ extrapyramidal events (moderate or severe) ‐ short term </h5> <p><a href="./references#CD011831-bbs2-0001" title="ChouinardG , AnnableL . Penfluridol in the treatment of newly admitted schizophrenic patients in a brief therapy unit. American Journal of Psychiatry1976;133(7):850‐3. [PUBMED: 937582] ChouinardG , AnnableL , CooperS . Antiparkinsonian drug administration and plasma levels of penfluridol, a new long‐acting neuroleptic. Communications in Psychopharmacology1977;1(4):325‐31. [PUBMED: 615695] ChouinardG , AnnableL , KolivakisTN . Penfluridol in the maintenance treatment of schizophrenic patients newly discharged from a brief therapy unit. Journal of Clinical Pharmacology1977;17(2‐3):162‐7. [PUBMED: 833344] ">Chouinard 1977</a> assessed extrapyramidal adverse effects at three weeks. No incidences of akathisia, dyskinesia, dystonia or tremor were observed. Two participants receiving penfluridol experienced rigidity, while no rigidity occurred in the chlorpromazine group, however, these data do not show a substantial difference between chlorpromazine and penfluridol for this outcome (1 RCT, n = 33, RR 0.15, 95% CI 0.01 to 2.90; <a href="./references#CD011831-fig-0009" title="">Analysis 1.4</a>). </p> </section> <section id="CD011831-sec-0135"> <h5 class="title">1.5 Adverse effects: 2b. Specific ‐ extrapyramidal events (moderate or severe) ‐ medium term </h5> <p>Overall, no differences between chlorpromazine and penfluridol were evident for extrapyramidal events (<a href="./references#CD011831-fig-0010" title="">Analysis 1.5</a>). </p> <section id="CD011831-sec-0136"> <h6 class="title">1.5.1 akathisia</h6> <p>Two studies reported data for akathisia , there was not a clear difference in effect between chlorpromazine and penfluridol (2 RCTs, n = 85, RR 0.19, 95% CI 0.04 to 1.06, low‐quality evidence). </p> </section> <section id="CD011831-sec-0137"> <h6 class="title">1.5.2 dyskinsia</h6> <p>Two studies reported data for dyskinesia, there was not a clear difference in effect between chlorpromazine and penfluridol (2 RCTs, n = 85, RR 0.97, 95% CI 0.14 to 6.52). </p> </section> <section id="CD011831-sec-0138"> <h6 class="title">1.5.3 dystonia</h6> <p>One study reported data for dystonia, with one person from each group experiencing dystonia (1 RCT, n = 29, RR 0.93, 95% CI 0.06 to 13.54). </p> </section> <section id="CD011831-sec-0139"> <h6 class="title">1.5.4 muscle spasm</h6> <p>One study (n = 56) reported data for muscle spasm, there was not a clear difference between chlorpromazine and penfluridol (RR 3.00, 95% CI 0.13 to 70.64). </p> </section> <section id="CD011831-sec-0140"> <h6 class="title">1.5.5 rigidity</h6> <p>Two studies (n = 70) reported data for this outcome, there was not a clear difference in effect between chlorpromazine and penfluridol (RR 0.22, 95% CI 0.04 to 1.20). </p> </section> <section id="CD011831-sec-0141"> <h6 class="title">1.5.6 tremor</h6> <p>Two studies (n = 85) reported data for this outcome, there was not a clear difference in effect between chlorpromazine and penfluridol RR 0.70, 95% CI 0.14 to 3.43). </p> </section> </section> <section id="CD011831-sec-0142"> <h5 class="title">1.6 Adverse effects: 2c. Specific ‐ anticholinergic (moderate or severe) ‐ short term</h5> <p>One study provided data for anticholinergic effects. Overall, no differences between chlorpromazine and penfluridol were evident for anticholingeric adverse effects in the short term (<a href="./references#CD011831-fig-0011" title="">Analysis 1.6</a>). </p> <section id="CD011831-sec-0143"> <h6 class="title">1.6.1 constipation</h6> <p>Six people receiving chlorpromazine and one person receiving penfluridol experienced constipation (1 RCT, n = 33, RR 4.42, 95% CI 0.60 to 32.71). </p> </section> <section id="CD011831-sec-0144"> <h6 class="title">1.6.2 dry mouth</h6> <p>Only one person in the chlorpromazine group experienced dry mouth (1 RCT, n = 33, RR 2.25, 95% CI 0.10 to 51.46). </p> </section> <section id="CD011831-sec-0145"> <h6 class="title">1.6.3 increased salivation</h6> <p>One person receiving penfluridol experienced an increase in salivation (1 RCT, n = 33, RR 0.25, 95% CI 0.01 to 5.72). </p> </section> </section> <section id="CD011831-sec-0146"> <h5 class="title">1.7 Adverse effects: 2d. Specific ‐ anticholinergic (moderate or severe) ‐ medium term </h5> <p>Again, only one study reported data. Overall, no differences between chlorpromazine and penfluridol were evident for anticholingeric adverse effects in the medium term (<a href="./references#CD011831-fig-0012" title="">Analysis 1.7</a>). </p> <section id="CD011831-sec-0147"> <h6 class="title">1.7.1 blurred vision</h6> <p>No people receiving chlorpromazine and one receiving penfluridol experienced blurred vision (1 RCT, n = 29, RR 0.31, 95% CI 0.01 to 7.09). </p> </section> <section id="CD011831-sec-0148"> <h6 class="title">1.7.2 constipation</h6> <p>Four people in the chlorpromazine group and one receiving penfluridol experienced constipation (1 RCT, n = 29, RR 3.73, 95% CI 0.47 to 29.49). </p> </section> <section id="CD011831-sec-0149"> <h6 class="title">1.7.3 dry mouth</h6> <p>One person receiving chlorpromazine experienced dry mouth (1 RCT, n = 29, RR 2.81, 95% CI 0.12 to 63.83). </p> </section> </section> <section id="CD011831-sec-0150"> <h5 class="title">1.8 Adverse effects: 2e. Specific ‐ central nervous system (moderate or severe) ‐ short term </h5> <p>Data from one study found no differences between chlorpromazine and penfluridol were evident for anticholingeric adverse effects in the short term (<a href="./references#CD011831-fig-0013" title="">Analysis 1.8</a>). </p> <section id="CD011831-sec-0151"> <h6 class="title">1.8.1 agitation</h6> <p>One person receiving chlorpromazine became agitated in the short term (1 RCT, n = 33, RR 2.25, 95% CI 0.10 to 51.46). </p> </section> <section id="CD011831-sec-0152"> <h6 class="title">1.8.2. drowsiness</h6> <p>FIve people receiving chlorpromazine became drowsy (1 RCT, n = 33, RR 8.25, 95% CI 0.49 to 137.94). </p> </section> <section id="CD011831-sec-0153"> <h6 class="title">1.8.3 dizziness</h6> <p>One participant in the chlorpromazine group and three in the penfluridol group experienced dizziness (1 RCT, n = 33, RR 0.25, 95% CI 0.03 to 2.12). </p> </section> <section id="CD011831-sec-0154"> <h6 class="title">1.8.4 insomnia</h6> <p>One person receiving chlorpromazine experienced insomnia (1 RCT, n = 33, RR 2.25, 95% CI 0.10 to 51.46). </p> </section> </section> <section id="CD011831-sec-0155"> <h5 class="title">1.9 Adverse effects: 2f. Specific ‐ central nervous system (moderate or severe) ‐ medium term </h5> <p>Two studies reported central nervous system effects data for the medium term, there was no clear differences between the two treatments for specific central nervous system effects. </p> <section id="CD011831-sec-0156"> <h6 class="title">1.9.1 drowsiness</h6> <p>Two studies showed no evidence of a clear difference between the two treatments for drowsiness (2 RCTs, n = 85, RR 1.05, 95% CI 0.54 to 2.05). </p> </section> <section id="CD011831-sec-0157"> <h6 class="title">1.9.2 dizziness</h6> <p>One study reported data for dizziness. One person in the chlorpromazine group and two in the penfluridol group experienced dizziness (1 RCT, n = 29, RR 0.47, 95% CI 0.05 to 4.60). </p> </section> <section id="CD011831-sec-0158"> <h6 class="title">1.9.3 excitement</h6> <p>One study reported data for excitement. One person in the chlorpromazine group experienced excitement (1 RCT, n = 29, RR 2.81, 95% CI 0.12 to 63.83). </p> </section> <section id="CD011831-sec-0159"> <h6 class="title">1.9.4 faintness</h6> <p>One study reported data for faintness. Two participants from each group experienced faintness (1 RCT, n = 29, RR 0.93, 95% CI 0.15 to 5.76). </p> </section> <section id="CD011831-sec-0160"> <h6 class="title">1.9.5 insomnia</h6> <p>Two studies reported data for insomnia. There was evidence of a clear difference, favouring chlorpromazine (2 RCTs, n = 85, RR 0.17, 95% CI 0.03 to 0.93). </p> </section> </section> <section id="CD011831-sec-0161"> <h5 class="title">1.10 Adverse effects: 2g. Specific ‐ various other effects (moderate or severe) ‐ short term </h5> <p>Two studies provided data for various other effects. One reported on heartburn and the other reported on systemic allergic reaction. Chlorpromazine was no different in its effect compared to penfluridol for various other short‐term effects (<a href="./references#CD011831-fig-0015" title="">Analysis 1.10</a>). </p> <section id="CD011831-sec-0162"> <h6 class="title">1.10.1 heartburn</h6> <p>One study (n = 33) provided data for heartburn. No one experienced heartburn in either group. </p> </section> <section id="CD011831-sec-0163"> <h6 class="title">1.10.2 increased alkaline phosphatase, bilirubin, SGOT (serum glutamic oxaloacetic transaminase) </h6> <p>One study found no evidence of a difference between the two treatments (1 RCT, n = 56, RR 0.33 95% CI 0.01 to 7.85) </p> </section> <section id="CD011831-sec-0164"> <h6 class="title">1.10.3 Systemic allergic reaction</h6> <p>One study provided data. Three people in the chlorpromazine group experienced systemic allergic reaction (1 RCT, n = 33, RR 5.25, 95% CI 0.29 to 94.14). </p> </section> </section> <section id="CD011831-sec-0165"> <h5 class="title">1.11 Adverse effects: 2h. Specific ‐ various other effects (moderate or severe) ‐ medium term </h5> <p>Various other adverse effects were measured in the medium term by one study . No clear difference was seen between the two treatments for any of these effects <a href="./references#CD011831-fig-0016" title="">Analysis 1.11</a>. </p> <section id="CD011831-sec-0166"> <h6 class="title">1.11. 1 depression</h6> <p>(1 RCT, n = 29, RR 0.19, 95% CI 0.01 to 3.60).</p> </section> <section id="CD011831-sec-0167"> <h6 class="title">1.11.2 decreased sexual drive</h6> <p>(1 RCT, n = 29, RR 0.47, 95% CI 0.05 to 4.60).</p> </section> <section id="CD011831-sec-0168"> <h6 class="title">1.11.3 impotence</h6> <p>(1 RCT, n = 29, RR 2.81, 95% CI 0.12 to 63.83).</p> </section> <section id="CD011831-sec-0169"> <h6 class="title">1.11.4 photosensitivity</h6> <p>(1 RCT, n = 29, RR 2.81, 95% CI 0.12 to 63.83).</p> </section> <section id="CD011831-sec-0170"> <h6 class="title">1.11.5 poor appetite</h6> <p>(1 RCT, n = 29, RR 0.93, 95% CI 0.06 to 13.54).</p> </section> </section> <section id="CD011831-sec-0171"> <h5 class="title">1.12 Leaving the study early: 1a. Any reason</h5> <p>Pooled data from three studies showed no clear medium‐term differences between penfluridol and chlorpromazine (3 RCTs, n = 130, RR 1.21. 95% CI 0.83 to 1.77, low‐quality evidence; <a href="./references#CD011831-fig-0017" title="">Analysis 1.12</a>). </p> </section> <section id="CD011831-sec-0172"> <h5 class="title">1.13 Leaving the study early: 1b. Due to adverse events</h5> <p>Two studies found no clear differences, in either short or medium term, when leaving early was due to adverse effects (<a href="./references#CD011831-fig-0018" title="">Analysis 1.13</a>) </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011831-sec-0173" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011831-sec-0173"></div> <section id="CD011831-sec-0174"> <h3 class="title" id="CD011831-sec-0174">Summary of main results</h3> <p>The summary below shows the outcomes selected for the <a href="./full#CD011831-tbl-0001">summary of findings Table for the main comparison</a> and addresses the main findings of this review. </p> <section id="CD011831-sec-0175"> <h4 class="title">1. Service utilisation: hospital readmission</h4> <p>There was only one study reporting two participants on penfluridol who were readmitted (due to depression). There was no clear differences between the drugs, but this important outcome was only reported in one tiny study (n = 29) and data quality have to be considered low. Best evidence highlights no difference. but the best evidence is poor. </p> </section> <section id="CD011831-sec-0176"> <h4 class="title">2. Global state</h4> <p>This is not a difficult outcome to record. No study reported on a binary outcome and the continuous data‐measured by Clinical Global Impression (CGI) were unusable (standard deviations of means were not reported in both included studies). No study reported on relapse as the other aspect of global state. </p> </section> <section id="CD011831-sec-0177"> <h4 class="title">3. Mental state</h4> <p>There is, at least, consistency across outcomes. Again, no study reported on a binary outcome and the continuous data were unusable (standard deviations of means were not reported in both included studies). It is easy to unfairly judge pioneering studies of the past by standards of today, but we think it unlikely that the participants in these trials gave informed consent to have data squandered. </p> </section> <section id="CD011831-sec-0178"> <h4 class="title">4. Adverse effects/events</h4> <section id="CD011831-sec-0179"> <h5 class="title">4.1 Extrapyramidal adverse events‐akathisia</h5> <p>We chose this medium‐term outcome because two studies reported on it. Data quality were low, trials were very small (2 RCTs, N = 85) and results equivocal, but there was a suggestion that should studies have been larger, the chlorpromazine group would have experienced less akathisia. Penfluridol, with a relatively higher potency, would be expected to induce more extrapyramidal side effects than chlorpromazine. However, the small sample size and probable reporting bias could mean little difference between the two drugs regarding extrapyramidal adverse effects was observed. </p> </section> <section id="CD011831-sec-0180"> <h5 class="title">4.2 Death</h5> <p>The lifetime incidence of suicide in people with schizophrenia is estimated to be 10% to 13% (<a href="./references#CD011831-bbs2-0015" title="CaldwellCB , GottesmanII . Schizophrenia‐‐a high‐risk factor for suicide: clues to risk reduction. Suicide and Life‐Threatening Behavior1992;22(4):479‐93. [PUBMED: 1488792] ">Caldwell 1992</a>). Sudden death as an adverse effect of antipsychotic drugs has been shown to have an incidence rate ratio of 1.99 (<a href="./references#CD011831-bbs2-0042" title="ManuP , KaneJM , CorrellCU . Sudden deaths in psychiatric patients. Journal of Clinical Psychiatry2011;72(7):936‐41. [PUBMED: 21672496] ">Manu 2011</a>). There was no report of death in the short and small included studies. Of course this is an important effect/event but, in retrospect, it might not have been wise to present this in the 'Summary of findings' as we would always have been unlikely to detect this rare event. </p> </section> </section> <section id="CD011831-sec-0181"> <h4 class="title">5. Leaving the study early</h4> <p>Leaving the study early may be the result of a multitude of reasons including lack of efficacy, adverse effects or an unacceptable study design. All in all, similar numbers of participants left early from each treatment group, neither drug was worse or better than the other. Nearly half of those entered into the studies left or were withdrawn early. On one hand, this could reflect a real‐world situation, attrition is often high, but there is the worry that these studies not convincingly reflecting care in routine practice, had any authority they had further eroded by loss to follow‐up. </p> </section> </section> <section id="CD011831-sec-0182"> <h3 class="title" id="CD011831-sec-0182">Overall completeness and applicability of evidence</h3> <section id="CD011831-sec-0183"> <h4 class="title">1. Completeness</h4> <p>These are old, small and limited studies. Much data were wasted because of poor reporting and more were never recorded. These are two important drugs and we do not have anywhere near a complete picture of their comparative effects. </p> </section> <section id="CD011831-sec-0184"> <h4 class="title">2. Applicability</h4> <p>Studies in this review included people in both outpatient and inpatient settings. People in the trials were often chronically unwell. This is an important group of people, but not inclusive of everyone with schizophrenia. Trials are also three to four decades old. In many places services have changed considerably in that time, in others, less so. What evidence we have is thin, and its applicability problematic. </p> </section> </section> <section id="CD011831-sec-0185"> <h3 class="title" id="CD011831-sec-0185">Quality of the evidence</h3> <p>The quality of the current evidence is low, based on ratings generated though GRADE (<a href="./references#CD011831-bbs2-0050" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In Higgins JPT, Green S editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011</a>). None of the studies reported how randomisation was achieved and only one trial described the method of allocation concealment. Although studies were reported as double‐blinded, none clearly described whether assessors were blinded to the treatment groups. All scale data were reported as means without standard deviations for the main results. Most results were presented in the text with authors simply reporting that results were statistically significant or not, but they did not report statistical measures of probability (P values) or the confidence interval. Although P values are influenced by the strength of the association, they also depend on the sample size of the groups. It is sometimes possible to extract raw data from P values, but their exact values are needed. In the reviewed studies this was not possible, because they were reported as ’P &lt; 0.05’ or ’P &lt; 0.001’. </p> </section> <section id="CD011831-sec-0186"> <h3 class="title" id="CD011831-sec-0186">Potential biases in the review process</h3> <section id="CD011831-sec-0187"> <h4 class="title">1. Adding the old to the new</h4> <p>We have found no time‐related differences in studies within this review and no indication of change of the effect size over time. Synthesis of the results of studies seems justified. </p> </section> <section id="CD011831-sec-0188"> <h4 class="title">2. Failing to identify old trials</h4> <p>We identified trials by meticulous searching, including handsearching old files. Nevertheless, it may be difficult to avoid some bias from not identifying long‐lost studies. </p> </section> <section id="CD011831-sec-0189"> <h4 class="title">3. Failing to identify other language trials</h4> <p>We identified trials in other languages by searching specialist databases. This should have identified, for example, Chinese studies. However, there is always a danger of failing to identify studies and especially if published in languages other than English. It seems unlikely, however, that we have failed to find large important studies. </p> </section> </section> <section id="CD011831-sec-0190"> <h3 class="title" id="CD011831-sec-0190">Agreements and disagreements with other studies or reviews</h3> <p>To our knowledge, there is no previous review specifically comparing chlorpromazine with penfluridol (<a href="#CD011831-tbl-0002">Table 1</a>). In another Cochrane study of penfluridol in schizophrenia, penfluridol has been suggested to have no significant difference with any other typical antipsychotics in terms of global state, mental state, attrition, and requiring antiparkinsonian medication (<a href="./references#CD011831-bbs2-0051" title="SoaresBG , Silva de LimaM . Penfluridol for schizophrenia. Cochrane Database of Systematic Reviews2006, Issue 2. [DOI: 10.1002/14651858.CD002923.pub2; PUBMED: 16625563] ">Soares 2006</a>). Compared with placebo, chlorpromazine has shown to improve global state and reduce relapse rate and attrition significantly (<a href="./references#CD011831-bbs2-0006" title="AdamsCE , RathboneJ , ThornleyB , ClarkeM , BorrillJ , WahlbeckK , et al. Chlorpromazine for schizophrenia: a Cochrane systematic review of 50 years of randomised controlled trials. BMC Medicine2005;3:15. [PUBMED: 16229742] ">Adams 2005</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011831-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/urn:x-wiley:14651858:media:CD011831:CD011831-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_t/tCD011831-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Chlorpromazine structure" data-id="CD011831-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_n/nCD011831-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Chlorpromazine structure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/full#CD011831-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_n/nCD011831-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011831-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/urn:x-wiley:14651858:media:CD011831:CD011831-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_t/tCD011831-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Penfluridol structure" data-id="CD011831-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_n/nCD011831-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Penfluridol structure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/full#CD011831-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_n/nCD011831-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011831-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/urn:x-wiley:14651858:media:CD011831:CD011831-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_t/tCD011831-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD011831-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_n/nCD011831-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/full#CD011831-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_n/nCD011831-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011831-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/urn:x-wiley:14651858:media:CD011831:CD011831-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_t/tCD011831-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011831-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_n/nCD011831-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/full#CD011831-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_n/nCD011831-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011831-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/urn:x-wiley:14651858:media:CD011831:CD011831-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_t/tCD011831-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011831-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_n/nCD011831-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/full#CD011831-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_n/nCD011831-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011831-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/urn:x-wiley:14651858:media:CD011831:CD011831-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_t/tCD011831-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus PENFLURIDOL, Outcome 1 Service utilisation: 1. Hospital readmission." data-id="CD011831-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_n/nCD011831-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus PENFLURIDOL, Outcome 1 Service utilisation: 1. Hospital readmission. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/references#CD011831-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_n/nCD011831-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011831-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/urn:x-wiley:14651858:media:CD011831:CD011831-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_t/tCD011831-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus PENFLURIDOL, Outcome 2 Adverse effects: 1a. General ‐ needing antiparkinsonian medication." data-id="CD011831-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_n/nCD011831-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus PENFLURIDOL, Outcome 2 Adverse effects: 1a. General ‐ needing antiparkinsonian medication. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/references#CD011831-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_n/nCD011831-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011831-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/urn:x-wiley:14651858:media:CD011831:CD011831-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_t/tCD011831-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus PENFLURIDOL, Outcome 3 Adverse effects: 1b. General ‐ need to reduce antipsychotic dose due to side effects." data-id="CD011831-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_n/nCD011831-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus PENFLURIDOL, Outcome 3 Adverse effects: 1b. General ‐ need to reduce antipsychotic dose due to side effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/references#CD011831-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_n/nCD011831-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011831-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/urn:x-wiley:14651858:media:CD011831:CD011831-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_t/tCD011831-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus PENFLURIDOL, Outcome 4 Adverse effects: 2a. Specific ‐ extrapyramidal events (moderate or severe) ‐ short term." data-id="CD011831-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_n/nCD011831-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus PENFLURIDOL, Outcome 4 Adverse effects: 2a. Specific ‐ extrapyramidal events (moderate or severe) ‐ short term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/references#CD011831-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_n/nCD011831-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011831-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/urn:x-wiley:14651858:media:CD011831:CD011831-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_t/tCD011831-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus PENFLURIDOL, Outcome 5 Adverse effects: 2b. Specific ‐ extrapyramidal events (moderate or severe) ‐ medium term." data-id="CD011831-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_n/nCD011831-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus PENFLURIDOL, Outcome 5 Adverse effects: 2b. Specific ‐ extrapyramidal events (moderate or severe) ‐ medium term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/references#CD011831-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_n/nCD011831-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011831-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/urn:x-wiley:14651858:media:CD011831:CD011831-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_t/tCD011831-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus PENFLURIDOL, Outcome 6 Adverse effects: 2c. Specific ‐ anticholinergic (moderate or severe) ‐ short term." data-id="CD011831-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_n/nCD011831-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus PENFLURIDOL, Outcome 6 Adverse effects: 2c. Specific ‐ anticholinergic (moderate or severe) ‐ short term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/references#CD011831-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_n/nCD011831-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011831-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/urn:x-wiley:14651858:media:CD011831:CD011831-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_t/tCD011831-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus PENFLURIDOL, Outcome 7 Adverse effects: 2d. Specific ‐ anticholinergic (moderate or severe) ‐ medium term." data-id="CD011831-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_n/nCD011831-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus PENFLURIDOL, Outcome 7 Adverse effects: 2d. Specific ‐ anticholinergic (moderate or severe) ‐ medium term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/references#CD011831-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_n/nCD011831-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011831-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/urn:x-wiley:14651858:media:CD011831:CD011831-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_t/tCD011831-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus PENFLURIDOL, Outcome 8 Adverse effects: 2e. Specific ‐ central nervous system (moderate or severe) ‐ short term." data-id="CD011831-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_n/nCD011831-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus PENFLURIDOL, Outcome 8 Adverse effects: 2e. Specific ‐ central nervous system (moderate or severe) ‐ short term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/references#CD011831-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_n/nCD011831-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011831-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/urn:x-wiley:14651858:media:CD011831:CD011831-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_t/tCD011831-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus PENFLURIDOL, Outcome 9 Adverse effects: 2f. Specific ‐ central nervous system (moderate or severe) ‐ medium term." data-id="CD011831-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_n/nCD011831-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus PENFLURIDOL, Outcome 9 Adverse effects: 2f. Specific ‐ central nervous system (moderate or severe) ‐ medium term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/references#CD011831-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_n/nCD011831-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011831-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/urn:x-wiley:14651858:media:CD011831:CD011831-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_t/tCD011831-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus PENFLURIDOL, Outcome 10 Adverse effects: 2g. Specific ‐ various other effects (moderate or severe) ‐ short term." data-id="CD011831-fig-0015" src="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_n/nCD011831-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus PENFLURIDOL, Outcome 10 Adverse effects: 2g. Specific ‐ various other effects (moderate or severe) ‐ short term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/references#CD011831-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_n/nCD011831-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011831-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/urn:x-wiley:14651858:media:CD011831:CD011831-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_t/tCD011831-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus PENFLURIDOL, Outcome 11 Adverse effects: 2h. Specific ‐ various other effects (moderate or severe) ‐ medium term." data-id="CD011831-fig-0016" src="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_n/nCD011831-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus PENFLURIDOL, Outcome 11 Adverse effects: 2h. Specific ‐ various other effects (moderate or severe) ‐ medium term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/references#CD011831-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_n/nCD011831-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011831-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/urn:x-wiley:14651858:media:CD011831:CD011831-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_t/tCD011831-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus PENFLURIDOL, Outcome 12 Leaving the study early: 1a. Any reason." data-id="CD011831-fig-0017" src="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_n/nCD011831-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus PENFLURIDOL, Outcome 12 Leaving the study early: 1a. Any reason. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/references#CD011831-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_n/nCD011831-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011831-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/urn:x-wiley:14651858:media:CD011831:CD011831-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_t/tCD011831-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus PENFLURIDOL, Outcome 13 Leaving the study early: 1b. Due to adverse events." data-id="CD011831-fig-0018" src="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_n/nCD011831-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus PENFLURIDOL, Outcome 13 Leaving the study early: 1b. Due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/references#CD011831-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/media/CDSR/CD011831/image_n/nCD011831-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD011831-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Suggested design of study</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Methods</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised, fully explicit description of methods of randomisation and allocation concealment.<br/> Blinding: single‐blind or double‐blind, but tested.<br/> Setting: anywhere.<br/> Duration: follow‐up to at least 52 weeks. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diagnosis: schizophrenia.<br/> N = 300.*<br/> Age: adults.<br/> Sex: both. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Chlorpromazine: oral‐maximum around 400 mg/day. N = 150.</p> <p>2. Penfluridol: oral‐maximum around 80 mg/week. N = 150.</p> <p>Both groups could receive antiparkinsonian medication as required.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Service utilisation: Hospital admission, time to admission.</p> <p>Global state: Clinically significant response in global state, relapse.</p> <p>Mental state: Clinically significant response in mental state.</p> <p>Adverse effects: Clinically significant extrapyramidal side effects, death.</p> <p>Leaving the study early.</p> <p>Functioning: Employed, days working, in supportive relationship, healthy days.</p> <p>Economic outcomes.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Notes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>* Powered to be able to identify a difference of ˜ 20% between groups for primary outcome with adequate degree of certainty. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Suggested design of study</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/full#CD011831-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011831-tbl-0001"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Chlorpromazine versus Penfluridol for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> hospital inpatients and outpatients<br/> <b>Intervention:</b> Chlorpromazine versus penfluridol </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk<sup>3</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Penfluridol</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Chlorpromazine</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Service utilisation: hospital admission</b> (short term) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>150 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b> <br/> (1 to 540) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.19 (0.01 to 3.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low <sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: clinically important change in global state</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported 'clinically important change in global state'. Change in global state was measure using global state scales but all data were presented without SD. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: relapse</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: clinically important change in mental state</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported 'clinically important change in mental state'. Change in mental state was measure using mental state scales but all data were presented without SD. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effect/event: clinically important extrapyramidal adverse events ‐ akathisia</b> (medium term) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>38 per 1000</b> <br/> (8 to 212) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.19</b> </p> <p>(0.04 to 1.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85<br/> (2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low <sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The same studies reported data for other extrapyramidal adverse events such as rigidity, tremor, dystonia and dyskinesia. There was no observable difference between chlorpromazine and penfluridol regarding any of these adverse effects. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effect/event: death</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 RCTs</p> <p>(0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No deaths reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Leaving the study early: any reason</b> (medium term) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>484 per 1000</b> <br/> (332 to 708) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.21</b> </p> <p>(0.83 to 1.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130<br/> (3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low <sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> risk ratio; <b>SD:</b> standard deviation </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Serious risk of bias: downgraded by one level ‐ study had an unclear risk of bias for random sequence generation and blinding of assessors.<br/> <sup>2</sup> Serious risk of imprecision: downgraded by one level ‐ studies had small sample sizes and number of events.<br/> <sup>3</sup> We have used the risk of an event in the penfluridol group within the trial/s the benchmark, rounding to nearest five for clarity of presentation in the table. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/full#CD011831-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011831-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Cochrane reviews on chlorpromazine for people with schizophrenia</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Review title</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reference</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acetophenazine versus chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011831-bbs2-0012" title="BazrafshanA , ZareM , OkhovatiM , Shamsi MeimandiM . Acetophenazine versus chlorpromazine for schizophrenia. Cochrane Database of Systematic Reviews2015, Issue 4. [DOI: 10.1002/14651858.CD011662] ">Bazrafshan 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine dose for people with schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011831-bbs2-0021" title="DudleyK , LiuX , DeHanS . Chlorpromazine dose for people with schizophrenia. Cochrane Database of Systematic Reviews2017, Issue 4. [DOI: 10.1002/14651858.CD007778.pub2; CD007778] ">Dudley 2009</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cessation of medication for people with schizophrenia already stable on chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011831-bbs2-0010" title="AlmerieMQ , AlkhateebH , EssaliA , MatarHE , RezkE . Cessation of medication for people with schizophrenia already stable on chlorpromazine. Cochrane Database of Systematic Reviews2007, Issue 1. [DOI: 10.1002/14651858.CD006329; CD006329] ">Almerie 2007</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus atypical antipsychotic drugs for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011831-bbs2-0049" title="SahaKB , BoL , ZhaoS , XiaJ , SampsonS , ZamanRU . Chlorpromazine versus atypical antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD010631.pub2] ">Saha 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus clotiapine for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Developing protocol</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus haloperidol for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011831-bbs2-0039" title="LeuchtC , KitzmantelM , KaneJ , LeuchtS , ChuaWLLC . Haloperidol versus chlorpromazine for schizophrenia. Cochrane Database of Systematic Reviews2008, Issue 1. [DOI: 10.1002/14651858.CD004278.pub2; CD004278] ">Leucht 2008</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus metiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011831-bbs2-0057" title="ZareM , BazrafshanA . Chlorpromazine versus metiapine for schizophrenia. Cochrane Database of Systematic Reviews2017, Issue 3. [DOI: 10.1002/14651858.CD011655.pub2] ">Zare 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus penfluridol for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Current review</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus piperacetazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011831-bbs2-0024" title="Eslami ShahrbabakiM , SharafkhaniR , DehnaviehR , ValiL . Chlorpromazine versus piperacetazine for schizophrenia. Cochrane Database of Systematic Reviews2015, Issue 6. [DOI: 10.1002/14651858.CD011709] ">Eslami 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus placebo for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011831-bbs2-0007" title="AdamsCE , AwadGA , RathboneJ , ThornleyB , Soares‐WeiserK . Chlorpromazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews2014, Issue 1. [DOI: 10.1002/14651858.CD000284.pub3; PUBMED: 24395698] ">Adams 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine for psychosis induced aggression or agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011831-bbs2-0008" title="AhmedU , JonesH , AdamsCE . Chlorpromazine for psychosis induced aggression or agitation. Cochrane Database of Systematic Reviews2010, Issue 4. [DOI: 10.1002/14651858.CD007445.pub2; CD007445] ">Ahmed 2010</a> </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Cochrane reviews on chlorpromazine for people with schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/full#CD011831-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011831-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">CHLORPROMAZINE versus PENFLURIDOL</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Service utilisation: 1. Hospital readmission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.01, 3.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.01, 3.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse effects: 1a. General ‐ needing antiparkinsonian medication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.51, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.46, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.43, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse effects: 1b. General ‐ need to reduce antipsychotic dose due to side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.26, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse effects: 2a. Specific ‐ extrapyramidal events (moderate or severe) ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 akatisia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 dyskinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 dystonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 rigidity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.01, 2.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse effects: 2b. Specific ‐ extrapyramidal events (moderate or severe) ‐ medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 akathisia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.04, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 dyskinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.14, 6.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 dystonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.06, 13.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 muscle spasm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 70.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 rigidity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.04, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6 tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.14, 3.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse effects: 2c. Specific ‐ anticholinergic (moderate or severe) ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.42 [0.60, 32.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.25 [0.10, 51.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 increased salivation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.01, 5.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse effects: 2d. Specific ‐ anticholinergic (moderate or severe) ‐ medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 blurred vision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.01, 7.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.73 [0.47, 29.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.81 [0.12, 63.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Adverse effects: 2e. Specific ‐ central nervous system (moderate or severe) ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.25 [0.10, 51.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.25 [0.49, 137.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.03, 2.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.25 [0.10, 51.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Adverse effects: 2f. Specific ‐ central nervous system (moderate or severe) ‐ medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.54, 2.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.05, 4.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 excitement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.81 [0.12, 63.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 faintness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.15, 5.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5 insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.03, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Adverse effects: 2g. Specific ‐ various other effects (moderate or severe) ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 heartburn</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 increased alkaline phosphatase, bilirubin, SGOT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 systemic allergic reaction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.25 [0.29, 94.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Adverse effects: 2h. Specific ‐ various other effects (moderate or severe) ‐ medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.01, 3.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 decreased sexual drive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.05, 4.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 impotence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.81 [0.12, 63.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4 photosensitivity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.81 [0.12, 63.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.5 poor appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.06, 13.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Leaving the study early: 1a. Any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.83, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Leaving the study early: 1b. Due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.75 [0.39, 116.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.72, 3.28]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">CHLORPROMAZINE versus PENFLURIDOL</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011831.pub2/references#CD011831-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011831.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD011831-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD011831-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011831-note-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011831-note-0005">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD011831-note-0004">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD011831-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD011831-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011831-note-0010">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011831\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011831\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011831\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011831\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011831\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011831\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011831\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011831\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011831\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011831\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011831\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011831\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011831\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011831\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011831\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011831\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011831\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011831\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=8ranHhTh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011831.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011831.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011831.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011831.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011831.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740720117324"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011831.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740720117328"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011831.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918df9577dad9377',t:'MTc0MDcyMDExNy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 